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Cancer, a growing health problem around the world, affects millions of people every year, so that 
innovative anticancer drugs with specific molecular mechanisms of action are essential in 
chemotherapeutic treatment to kill specific cancer types, and to overcome toxic side effects as well 
as chemoresistance. Impaired apoptosis and autophagy seem to play a central role in cancer 
development and constantly limit the efficacy of conventional cytotoxic therapies. Indeed, current 
research efforts are focused on a deeper understanding of the cellular response and/or resistance to 
anticancer treatments, including the role of cell death pathways activation by 
metallochemotherapeutics such as novel ruthenium-based drugs, proposed as safe and effective 
potential drugs. Moreover, in the last few years nanostructures have gained considerable interest for 
the safe delivery of therapeutic agents. 
In these fields, we have recently developed a novel approach for the in vivo delivery of novel Ru(III) 
complexes, preparing stable nucleolipidic-based formulations endowed with considerable 
antiproliferative activity. In particular, aiming at improving the suitability of Ru(III) complexes in 
biological environment - specifically of AziRu, a pyridine NAMI-A analog - as well as their 
advantages for biomedical applications, we have designed innovative nanoaggregates by means of 
high-functionalized nucleolipidic Ru(III) complexes, ad hoc mixed with zwitterionic or cationic 
lipids to provide stable and biocompatible liposome formulations for cancer therapy.   
Hence, in line with this project and by in vitro bioscreens in the frame of preclinical studies, we have 
focused on the ability of nucleolipidic ruthenium-containing liposomes to inhibit cancer proliferation 
in selected human breast cancer models in vitro, possibly by predisposing cells to programmed cell 
death. In the case, breast cancer is the second most common cancer worldwide after lung cancer, the 
fifth most common cause of cancer death, and the leading cause of cancer death in women. The global 
weight of breast cancer exceeds all other cancers and the incidence rates of breast cancer are 
increasing. Luckily, the total survival rates of most cancers have been prolonged due to the energies 
of both clinicians and scientists. Behind an in-depth microstructural characterization, we have herein 
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demonstrated that the most efficient ruthenium-containing cationic nanoaggregates we have hitherto 
developed are able to elicit both extrinsic and intrinsic apoptosis, as well as autophagy. Using 
especially designed fluorescent formulations and confocal microscopy approaches for targeted 
studies of intracellular localization, in addition to subcellular fractionation and inductively coupled 
plasma-mass spectrometry (ICP-MS) to assess cellular accumulation, we have detected, unlike the 
naked AziRu, a wide both cytosolic and nuclear distribution of the active Ru(III) complex. This would 
allow the ruthenium to interact with both mitochondrial and nuclear molecular targets, accounting for 
its ability to inhibit breast cancer cell proliferation by the activation of multiple cell death pathways, 
possibly via mitochondrial perturbations involving Bcl-2 family members, and Ru(III) ions 
incorporation into double-stranded DNA. To limit chemoresistance and counteract uncontrolled 
proliferation, multiple cell death pathways activation is a promising strategy for targeted therapy 
development, especially in aggressive cancer diseases such as triple-negative breast cancer with 
limited treatment options. The heterogeneity of breast cancers makes them both a fascinating and 
difficult solid tumour to diagnose and treat. Triple-negative breast cancers in particular are difficult 
to define lacking Her2 expression, estrogen and progesterone receptor, and do not respond to 
hormonal therapies or Her2-targeted therapies; hence, new systemic therapies are desperately needed. 
The oncology community needs for a new dawn of innovative and creative means to overcome these 
challenges so we can witness further breakthroughs. Moreover, allowing for the importance of the 
tumour microenvironment as well as of the stromal components playing both critical role in the 
tumourigenic process, the function of cancer-associated immune cell system and their cellular secrets 
were also investigated, in order to achieve a deeper understanding of the typical molecular pathways 
involved in the cross-talk between tumour components and stromal cells; this would allow to properly 
act on tumour microenvironment in order to further improve the efficacy of chemotherapy. In this 
case, the EPO/ESA treatment – commonly used in therapy for anaemia – can induce tumour 
progression and growth, because of its impact on the anti-cancer immune response. 
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So overall these outcomes discharge original knowledge in the field of anticancer therapy and on 
ruthenium-based candidate drugs, thus providing new insights for future optimized cancer treatment 
protocols.  
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1.1 Cancer: incidence and mortality patterns 
The term “cancer” indicates a group of diseases where abnormal cells divide without control 
and can invade neighboring tissues. Cancer cells can also spread to other parts of the body 
through the blood and lymphoma system. 
Cancer is an important condition, both in terms of the number of people affected and of the 
impacts on those people and people close to them. Millions new cancers are diagnosed 
annually worldwide, across over a lot of different cancer types. Each of these cancer types 
has different presenting features, though there may be overlap. Although there have been 
large advances in treatment and survival, with a half of cancer sufferers now living at least 
ten years after diagnosis, it remains the case that more than a quarter of all people alive now 
will die of cancer. 
Based on the EUCAN estimates (Foucher et al., 2014), more than 3.4 million new cases of 
cancer (excluding non-melanoma skin cancer) were diagnosed in Europe in 2012; almost 
80% of them in the European Union. The most common cancers were those of breast, large 
bowel, prostate and lung, all of which represented more than 1.7 million cases annually. The 
cancer with the largest number of incident and prevalent cases was breast cancer (464,000 
cases), while by far the largest number of deaths was due to lung cancer (353,000 deaths) 
(Ferlay et al., 2012). 
For women, there was a clear southeast-northwest gradient in incidence of all cancers 
(Figure 1) with the highest incidence in Denmark (European age-standardized rate, ASR(E) 
454 per 100,000) and the lowest in Greece (ASR(E) 192 per 100,000). There was a similar 
but less consistent pattern for males (Figure 2) with the highest incidence in France (ASR(E) 
551 per 100,000) and the lowest in Bosnia-Herzegovina (ASR(E) 254 per 100,000). A 
comprehensive overview of cancer patterns in Europe is provided elsewhere. 
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Figure 1. Estimated incidence of all cancers excluding non-melanoma skin, females, Europe 2012 (Ferlay et 
al., 2012). 
 
 
 
 
Figure 2. Estimated incidence of all cancers excluding non-melanoma skin, males, Europe 2012 (Ferlay et al., 
2012). 
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1.2 Most common therapeutic approaches 
The "surgery therapy" is the oldest and most effective strategy to eradicate the tumour, but 
its limits were clear in view of the small size of the tumour and its inaccessibility, or the 
extent of invasion, the presence of metastasis and, above all, the involvement of important 
organism structures (such as vases and nerves). Also, the radiation therapy is more efficient 
if the tumour is not largely diffused. Often it is used in combination with chemotherapy and/ 
or surgery. 
A more recent approach is the Immunotherapy, which consists in stimulating the immune 
sistem by administering a vaccine containing an antigen derived from tumours able to 
stimulate the production of antibodies or by direct somministration of antibodies monoclonal 
cells directed towards a precise type of tumour antigen. 
The use of chemotherapeutic agents is certainly the most widely used approach to reduce 
metastases as well as primary tumour, which is particularly important since the mortality of 
cancer patients is often attributable to the proliferation of metastases rather than the 
development of the primary tumour. 
In fact, if this can be surgically removed, drug therapy is the only choice for the treatment 
of metastases, which often develop before the tumour is diagnosed. 
It has spread from the second half of the twentieth century when research has led to the 
creation of a wide range of drugs that block tumour cell DNA replication by various 
mechanisms of action such as DNA alkylating agents to form a covalent bond with the purine 
or pyrimidine bases of the DNA), antimetabolites (such as folic acid analogs, pyrimidine 
analogs and purine analogs), antimitotes, blocking the cell division phase, topoisomerase 
inhibitors. 
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1.3 Breast cancer: clinical classification and standard of care 
Breast cancer is the most common type of diagnosed malignancy and the second leading 
cause of cancer death in women worldwide (Ferlay et al., 2015). Nowadays, most breast 
cancers are diagnosed early enough to be successfully treated with surgery, chemotherapy, 
radiotherapy, or a combination thereof. However, despite the success of screening 
programs and the development of adjuvant therapies, a significant percentage of breast 
cancer patients will suffer a metastatic disease that, to this day, remains incurable and 
justifies the search of new therapeutic strategies. Among the new therapies that have been 
developed in recent years, the emergence of targeted therapies has been a milestone in the 
fight against cancer (García-Aranda and Redondo, 2017). 
Clinically, breast cancer can be divided into distinct subtypes that have prognostic and 
therapeutic implications. Thanks to the deep sequencing of breast cancer genome and 
transcriptome, this heterogeneous disease has been classified into four major molecular 
subtypes of invasive breast cancer (HER2-enriched, luminal A, luminal B and basal-like) 
(Tamimi et al., 2012), with different prognosis and treatment response (Miller et al., 2017; 
Tamimi et al., 2012; García-Aranda and Redondo, 2017). 
▪ HER2-Enriched 
Human epidermal growth factor receptor 2 (HER2)-enriched mammary tumors have been 
extensively studied and are well described. Together with HER1 (EGFR/ErbB-1), HER3 
(ErbB-3), and HER4 (ErbB-4), HER2 (ErbB2/neu) is a member of the ErbB membrane 
tyrosine kinase receptors family, closely related to the transcription of signaling pathways 
leading to cell proliferation, differentiation and inhibition of apoptosis pathways (Segovia-
Mendoza et al., 2015). HER2 is constitutively activated in approximately 20-30% of breast 
cancers (Segovia-Mendoza et al., 2015). Given that HER2 overexpression is widely known 
to dysregulate cell proliferation in the aggressive HER2-positive breast cancers, this 
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protein represents an important therapeutic target for patients with this breast cancer 
subtype. Moreover, knowing that the presence of tumour-infiltrating lymphocytes was 
associated with favorable outcomes in HER2-positive and triple-negative breast cancer, 
immunotherapy (with immune checkpoint blockade) induced long-lasting responses and 
improved survival in hard-to-treat malignancies (ie, melanoma and non-small cell lung 
cancer), changing treatment paradigms in a variety of neoplastic diseases (Lambertini et 
al., 2017). 
The approved therapy is the humanized monoclonal antibody trastuzumab (Herceptin) that 
is able to blocks the extracellular domain of HER2. Although trastuzumab has dramatically 
improved the outcome for patients with this type of cancer, appearance of resistance is a 
frequent problem that has motivated the search of alternative therapies targeting this 
tyrosine kinase receptor. In this context, small kinase inhibitors like lapatinib/Tykeb, 
neratinib (Prove et al., 2016), gefitinib (Segovia-Mendoza et al., 2015), or afatinib (Zhang 
et al., 2014), have shown preclinical and clinical evidence in the treatment of HER2-
enriched tumors. 
However, identification of patients who are most likely to benefit from immune checkpoint 
blockade remains challenging, with many patients not responding to treatments and a 
significant financial cost. The combination of immune checkpoint blockade with 
conventional cancer treatments such as chemotherapy, radiotherapy, targeted therapies or 
with other immunotherapies is a promising strategy to potentiate its efficacy in breast 
cancer although further research is required to effectively identify who will respond to 
these immunotherapies (Solinas et al., 2017). 
▪ Hormone Receptor Positive (Luminal-A, Luminal-B) 
Both luminal-A and luminal-B breast cancer subtypes, which account for up to 75% of 
breast tumor cases (Zhang et al., 2015), are hormone receptor-positive (HR-positive), and, 
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therefore, they express estrogen receptors (ER), progesterone receptors (PR), and/or 
estrogen-responsive and ER-dependent gene products (Chang et al., 2012). As the estrogen 
hormone (17 β-estradiol) plays an important role during different hallmarks of cancer, 
luminal-A and luminal-B breast carcinomas are, theoretically, sensitive to hormone-
targeted treatments. Indeed, Tamoxifen (TMX, Nolvadex) is the most common drug used 
in clinical practice over the past decades as first-line treatment in pre- and post-menopausal 
women with ER-positive breast cancer (Carlson et al., 2003). However, although this 
competitive ER-receptor antagonist has shown a significant reduction of reappearance (40–
50%), and the risk of death from breast cancer (30–35%), the existence of an important 
number of cases with natural or acquired resistance to tamoxifen along with long-term 
toxicities has motivated the search for new approaches for HER2-enriched breast cancer 
patients (García-Aranda and Redondo, 2017). 
▪ Basal-Like 
Basal-like breast tumors are characterized by a gene-expression profile similar to that of 
the basal-myoepithelial layer of the normal breast along, with the absence of HER2 
overexpression and the absence or low levels of estrogen receptor expression (Foulkes et 
al., 2010). The triple negative breast cancer (TNBC) subtype, which constitutes 
approximately 80% of the basal-like tumors, accounts for approximately 10–15% of breast 
carcinomas, and is characterized by the lack of expression of both hormone receptors 
(estrogen and progesterone) and HER2-receptor over-expression (Dawood et al., 2010). 
For these reasons, both TNBC and basal-like breast cancers usually lead to an aggressive 
disease, with a high probability of metastasis (Foulkes et al., 2010), and with poor 
prognosis, which is due, in part, to the absence of an existing effective targeted therapy 
(García-Aranda and Redondo, 2017). 
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1.4 Several types of cell death induced by chemotherapeutics 
Cell death is the last fate of the life cycle of cells. In physiological condition, such as during 
development, accurate patterns of cell death determine the size and shape of limbs and other 
tissues (Ngabire and Kim, 2017). Cells can also die when they become damage or infected. 
In these and many other cases - in particular for cancer cells - cell death is not a random 
process but occurs by a programmed sequence of molecular events, in which the cell 
systematically destroys itself from within and is then eaten by other cells, without trace. 
Different pathways involved in cell death are known to date, and are mostly represented by 
apoptosis, autophagy and necrosis. Cells dying by apoptosis undergo characteristic 
morphological changes, such as shrinkage and condensation, cytoskeleton shock, the 
disassembling of nuclear envelope as well as condensation of nuclear chromatin. In this way, 
and also for the autophagy pathway, the cell dies neatly and is rapidly cleared away, without 
causing a damaging inflammatory response. In contrast, necrotic cells swell and burst, 
spilling their contents over their neighbors and eliciting an inflammatory response. 
 
 
 
                             
Figure 3. The three major cell death pathways. (Ngabire and Kim, 2017) 
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1.4.1 Necrosis 
Necrosis regroups a considerable variety of cell death pathways that share their loss of 
physiological structure of the cellular cytoplasmic membrane to which follows the dispersion 
of cytoplasmic elements. It can arise as a result of many events that affect cellular 
homeostasis or repeated extensive damage and both will cause cell death with loss of cellular 
integrity. Some examples are high temperature, repeated freeze/thaw series, or during other 
stressful situations. In these cases, necrosis can be considered as a passive process because 
there is not activation of specific pathways of proteins. Cytoplasmic cell membrane rupture 
may also be considered in the late steps of apoptotic or autophagic deaths, especially when 
phagocytosis does not suppress dead cell from circulation. As no signaling pathway is here 
implicated, it is mainly called secondary necrosis, to differentiate it from other programmed 
deaths such as apoptosis, necroptosis or autophagy. Necrosis is not entirely a result of pure 
risk or passive processes, since it can group well-organized successive events (Ngabire and 
Kim, 2017). In most cases, necrosis is linkely to be caused by energy depletion, which leads 
to metabolic defects and loss of the ionic gradients that normally exist across the cell 
membrane. One form of necrosis, called “necroptosis” (Yuan and Kroemer, 2010), is a form 
of programmed cell death that is triggered by a specific regulatory signal from other cells 
and dependent on a receptor-interacting protein kinase (RIP). This process demands the 
kinase activity of RIP3, and can lead to a quick cell death with characteristics specific to 
necrosis (Towers and Thorburn, 2016). 
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1.4.2 Apoptosis 
The process of programmed cell death, or apoptosis, is generally characterized by distinct 
morphological characteristics and energy-dependent biochemical mechanisms. It is 
considered a vital factor of several processes including normal cell turnover, correct 
development and functioning of the immune system, hormone-dependent atrophy, 
embryonic development and chemical-induced cell death. While inappropriate apoptosis, is 
a factor in many human conditions including neurodegenerative diseases, autoimmune 
disorders, ischemic damage as well as different types of tumour, where it is a mechanism 
typically dysregulated. 
Apoptosis is triggered by members of a specialized intracellular family proteases, which 
cleave specific sequences in numerous proteins inside the cell. These proteases, called 
caspases, have a cysteine residue at their active site and cleave their target proteins at specific 
aspartic acids residues. Caspases are synthetized in the cell as inactive precursors and are 
activated only during apoptosis. There are three major classes of apoptotic caspases: initiator 
caspases (caspase-2, -8, -9, -10), effectors or executioner caspases (caspase-3, -6, -7) and 
inflammatory caspases (caspase-1, -4, -5) (Cohen, 1997; Rai et al., 2005). Initiator caspases, 
as their name implies, begin the apoptotic process. In fact, an apoptotic signal causes the 
assembly of large protein platforms that bring multiple initiator caspases together into large 
complexes. Within these complexes, pairs of caspases associated to form dimers, resulting 
in protease activation. The principal role of the initiator caspases is the activation of the 
executioner caspases. As the former ones, also these latter ones exist as inactive dimers 
which rearrange to an active conformation after cleavage. One initiator caspase complex can 
activate many executioner caspases resulting in an amplifying proteolytic cascade. To date, 
research indicates that there are two main apoptotic pathways: the extrinsic - or death 
receptor pathway - and the intrinsic - or mitochondrial pathway (Elmore, 2007). 
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Furthermore, there is now clear evidence that the two pathways are linked and that molecules 
in one pathway can influence the other (Igney and Krammer, 2002). 
The intrinsic pathway is activated by a numerous of stress signals, such as DNA damage 
caused by chemo- and radiotherapies. Upon cellular stresses, a signal is transmitted to the 
mitochondria, leading to the mitochondrial outer membrane permeabilization (MOMP) and 
the release of apoptotic proteins. This crucial event in the intrinsic apoptosis pathway, is 
controlled by B cell lymphoma 2 (Bcl-2) family proapoptotic effector proteins Bax and Bak, 
which are activated by proapoptotic BH3-only Bcl-2 family proteins and antagonized by 
antiapoptotic Bcl-2 family proteins (i.e., Bcl-2, Bcl-XL, Bcl-B). 
Moreover, recent studies suggested the presence of an additional pathway that implies T-cell 
mediated cytotoxicity and perforin-granzyme-dependent killing of the cell (Figure 4) 
(Elmore, 2007). 
All the pathways converge on the same execution pathway. This pathway starts by the 
cleavage of caspase-3 and ends in several events, such as DNA fragmentation, degradation 
of cytoskeletal and nuclear proteins, cross-linking of proteins, formation of apoptotic bodies, 
expression of ligands for phagocytic cell receptors and finally uptake by phagocytic cells. 
However, the granzyme A pathway can activate a parallel, caspase-independent cell death 
pathway via single stranded DNA damage (Martinvalet et al., 2005). 
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Figure 4. Schematic illustration of apoptotic events. The two main pathways of apoptosis are extrinsic and 
intrinsic as well as a perforin/granzyme pathway. Each requires specific triggering signals to begin an energy-
dependent cascade of molecular events. Each pathway activates its own initiator caspase (8, 9, 10) which in 
turn will activate the executioner caspase-3. However, granzyme A works in a caspase-independent fashion. 
The execution pathway results in characteristic cytomorphological features including cell shrinkage, chromatin 
condensation, formation of cytoplasmic blebs and apoptotic bodies and finally phagocytosis of the apoptotic 
bodies by adjacent parenchymal cells, neoplastic cells or macrophages (Elmore, 2007). 
 
 
 
Dysfunction of apoptosis pathways can confer cancer-treatment resistance, as most 
conventional chemotherapies as well as radiotherapy depend on their ability to provoke 
apoptotic cell death in cancer cells. Therefore, apoptosis pathways can be therapeutically 
exploited for cancer treatment. 
Apoptosis is tightly regulated by the balance between pro- and anti-apoptotic proteins and 
becomes dysregulated when the balance between pro- and antiapoptotic proteins is altered. 
In human cancers, overexpression of antiapoptotic proteins is frequently observed and has 
been linked to tumour progression, treatment resistance, and poor prognosis. Therefore, 
targeting antiapoptotic proteins with the goal to recreate the apoptotic response has been 
considered as a promising cancer therapeutic strategy in the past decade (Bai and Wang, 
2013). 
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1.4.3 Autophagy 
Autophagy is an evolutionarily conserved lysosomal pathway involved in the turnover of 
long-lived proteins and organelles (Klionsky and Ohsumi, 1999; Meijer and Codogno, 
2004). To date, three forms of autophagy are known—chaperone-mediated autophagy, 
microautophagy, and macroautophagy (Ngabire and Kim, 2017). The latter one is the most 
referred to when autophagy is mentioned. Both differ from each other due to their initiation, 
the mechanisms involved and the mode of destruction during delivery to the lysosome. 
Autophagy is one of the most preserved cell death pathways, characterized by the 
elimination of large parts of cytoplasmic components after being consumed by a multilayer-
membrane-bound vesicle called an autophagosome. The autophagosomal membrane is 
derived from a pre-autophagosomal structure of uncertain origin (Mizushima et al., 2011; 
Mizushima and Komatsu, 2011). In mammalian cells, a structure called the phagophore 
contributes to the formation of the autophagosome (Fengsrud et al., 1995). A first step 
towards the formation of the autophagosome is the expansion of the pre-autophagosomal 
membrane. This step is dependent upon signaling molecules that modulate the activity and 
the expression of some “autophagy genes”. About cellular homeostasis, autophagy plays a 
dual role promoting both cell survival and cell death (Kang et al., 2007). Furthermore, in 
cancer cells, autophagy plays a major role -triggered in response to cellular stress, such as 
nutrient and growth factor starvation or hypoxia - acting as either tumour suppressor or 
tumour promoter (Kang et al., 2007). Such diverse role of autophagy largely depends on the 
type and genetic background of cancer cells (Elmore, 2007). In the tumour 
microenvironment, it is able to regulate the differentiation of macrophages into tumour-
associated macrophages (TAMs) and fibroblasts into cancer-associated fibroblasts (CAFs), 
the most abundantly components present in the tumour microenvironment.  
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Although autophagy is linked to multiple cancer-related pathways, the most relevant and 
best studied is phosphatidylinositol 3-kinase/protein kinase B/mammalian target of 
rapamycin (PI3kinase/Akt/mTOR) signaling pathway. In fact, this signaling pathway plays 
a major role in transmitting autophagic stimuli because of its ability to sense nutrient, 
metabolic and hormonal signals. In addition, autophagy, just because characterized by a flux 
of membrane from the formation of the autophagosome to the fusion with the lysosome, is 
regulated by GTPases, similarly to the vesicular transport along the exocytic/endocytic 
pathway (Meijer and Codogno, 2004). 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a soluble protein, distributed 
ubiquitously in mammalian tissues and cultured cells, that plays an important role in the 
autophagy process. During autophagy, autophagosomes engulf cytoplasmic components, 
including cytosolic proteins and organelles. Concomitantly, a cytosolic form of LC3 (LC3-
I) is conjugated to phosphatidylethanolamine (PE) to form LC3-phosphatidylethanolamine 
conjugate (LC3-II), which is recruited to autophagosomal membranes. This newly formed 
complex, LC3-II, is very important for the fusion of autophagosomes with lysosomes. As 
soon as this step is terminated, the autophagosome fuses with lysosomes, and from the 
fusion, will result in one double membrane vesicle called autolysosome. Simultaneously, 
LC3-II in autolysosomal lumen is degraded. Thus, lysosomal turnover of the 
autophagosomal marker LC3-II reflects starvation-induced autophagic activity, and 
detecting LC3 by immunoblotting or immunofluorescence has become a reliable method for 
monitoring autophagy and autophagy-related processes, including autophagic cell death 
(Tanida et al., 2008). 
Inadequate autophagy can be deleterious, as can be exorbitant activation, therefore 
autophagy in a cell must be strictly controlled. The induction together with the regulation of 
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autophagy has been well investigated, mostly in yeast, in mammalian cells, and in 
Drosophila. The formation and maturation of the autophagosome in the cytoplasm are 
controlled and regulated by a set of multiple proteins both related to autophagy (ATG 
proteins) (Figure 5). The preinitiation complex is formed first, and is made of different 
proteins (such as ULK1, FIP200 protein, and ATG13). Two major proteins regulate this 
complex: the mammalian target of rapamycin complex 1 (mTORC1) from the PI3k-Akt 
pathway which inhibits autophagy, and adenosine monophosphate (AMP)-activated protein 
kinase (AMPK) that inhibits mammalian target of rapamycin complex 1 (mTORC1) (Kim 
et al., 2011). This step marks the autophagy initiation phase. When ATP molecules are being 
consumed and not successfully replaced, AMP together with adenosine diphosphate (ADP) 
accumulate and activate AMPK. The activated AMPK initiates indirectly autophagy by 
suppressing the activity of mTORC1. Thus, the preinitiation complex plays a major role in 
the inhibition of mTORC1 and/or activation of AMPK. The preinitiation complex attracts 
and then activates another initiative complex with Beclin-1, a protein in the class III PI3K 
(Vps34), and a kinase protein Vps15. In addition, Beclin-1 is confined by antiapoptotic 
proteins like Bcl2 and Bcl-XL (Luo et al., 2010), and therefore inhibits the activity of the 
initiation complex. 
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Figure 5. Activation and regulation of autophagy (Ngabire and Kim, 2017). 
 
 
 
1.4.3.a) Apoptosis and autophagy: their molecular crosstalk  
Apoptosis and autophagy are in a complex crosstalk sharing molecular components that 
directly regulate them and can be triggered by common upstream signals (Fimia and 
Piacentini, 2010). Both processes can either induce cell death in a coordinated manner, or 
the cell can switch between the two responses in a mutually exclusive way. Consequently, 
autophagy can antagonize apoptotic cell death by promoting cell survival, and apoptosis-
associated caspase activation can disrupt the autophagic process. Understanding the 
interplay between these key processes in cancer and other diseases is fundamental for the 
development of successful therapy. In fact, the manipulation of autophagy for therapeutic 
purposes is crucial to recognize its role in both cytoprotection and cytotoxicity, since 
interfering with one type of cell death may activate another cell-damaging pathway.  
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1.5 Anticancer metal-based therapy: ruthenium complexes as a new class of 
chemotherapeutics 
In recent years, research efforts are focused on a deeper investigate and development of 
antineoplastic agents. Among these, metallodrugs represent a very important class of 
chemotherapeutics, exhibiting a wide range of interesting biological activities (McQuitty, 
2014). 
Cisplatin and its analogues have hitherto dominated the field of metal-based compounds 
endowed with high importance in cancer treatment, so that platinum-based drugs are 
currently the most widely used chemotherapeutics (Petrelli et al., 2016). Activation of 
cellular apoptosis caused by DNA targeting seems to be the most factor in causing 
bioactivity of cisplatin and its derivatives (Dasari and Tchounwou, 2014). Thanks to the 
evident clinical applications of these platinum-based drugs, in the field of inorganic 
biochemistry the number of researches to find other metallodrugs - that can be used for 
cancer therapy - has significantly increased. Although anticancer platinum compounds 
continue to be designed and synthesized through numerous different approaches in order to 
improve the therapeutic effects as well as to overcome their limitations, the use of transition 
metal compounds different to platinum has also attracted attention (Komeda and Casini, 
2012). In particular, ruthenium-based drugs have attracted great interest due to their lower 
toxicity, often associated with the ability to overcome the resistance encountered with 
platinum drugs. In fact, they possess several favorable chemical properties marking them as 
strong antitumour candidates in a rational drug discovery approach (Mühlgassner et al., 
2012). The major advantages of ruthenium complexes are related to their peculiar features, 
as for example: i) the facility to exchange O- with N-donor ligands similarly to platinum-
based drugs; ii) their octahedral geometry, which offers unique possibilities for the binding 
to nucleic acids; iii) the high versatility in terms of oxidation states, including II, III and 
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perhaps IV in the biological fluids; iv) the possibility to be transformed into poorly reactive 
prodrugs, with the ruthenium ion in the +3 oxidation state that can be reduced, and thus 
activated, selectively in solid tumour masses as a result of their low oxygen content 
(Mazuryk et al., 2012). 
Since the early 80’s, Alessio, Sava and co-workers have been pioneers in studying transition-
metal complexes in a biomedical perspective as potential anticancer agents, developing, 
among others, the very active Ru(III) complex ImH+ [trans-RuCl4(DMSO)Im-] called 
NAMI-A (Sava et al., 2002; Rademaker-Lakhai et al., 2004). This compound, with 
indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) and [Ru(η6-p-
cymene)Cl2(pta)](pta is 1,3,5-triaza-7-phosphaadamantane) (RAPTA-C), successfully 
completed phase I, has been introduced into advanced clinical trials currently (Sava et al., 
1999; Hartinger et al., 2008; Berndsen et al., 2017). Despite of their structural similarities 
(Figure 6), these Ru derivatives exhibit distinctly different anticancer effects (Frasca et al., 
1996; Mazuryk et al., 2012). In fact, while NAMI-A shows a remarkable and selective 
activity against cancer metastases, mostly of solid lung tumours, KP1019 present a high 
cytotoxic effect on primary cancers (Kapitza et al., 2005). 
 
 
 
Figure 6. Molecular structure of KP1019 (A), NAMI-A (B) and RAPTA-C (C) (Ranier et al., 2017). 
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Similar to KP1019 and NAMI-A, which are both based on a Ru III ion, the Ru II complex 
RAPTA-C also appears to be well tolerated in vivo showing less side-effects compared to 
platinum-based drugs (Weiss et al., 2014). However, RAPTA-C has recently demonstrated 
to exert a strong anti-angiogenic effect (Nowak-Sliwinska et al., 2011), similar to that of 
sorafenib, a clinically used anti-angiogenic small molecule drug (Weiss et al., 2014). 
Moreover, there are characteristics shared by RAPTA-C and NAMI-A, exhibiting limited 
direct cytotoxic effects on cancer cells in vitro as well as anti-metastatic behavior in vivo. 
NAMI-A has also presented an anti-angiogenic activity, demonstrated by its ability to induce 
and activate apoptosis cell death pathway in a spontaneously transformed human endothelial 
cell line (ECV304) through the inhibition of MEK/ERK signaling (Sanna et al., 2002). 
In these compounds, similarly to cisplatin, the chloride ligands of the ruthenium complex 
can be replaced by water molecules or hydroxide ions, leading to partial hydrolysis of the 
complex and poly-oxo species formation – ultimately responsible for the antimetastatic 
activity. 
Along with ligands release and/or substitution - which occurs rapidly under physiological 
conditions in vitro and in vivo - the biological reduction of ruthenium III complexes is a 
possible process, especially in high proliferating cells, thereby promoting a unique activation 
process of this kind of metal-based drug in tumour tissues (Ravera et al., 2004). 
Nevertheless, in the general uncertainty concerning their mechanism of action, it cannot be 
excluded that Ru III complexes, properly transported into tumour cells, can interact in their 
original redox status with potential molecular targets. Furthermore, the possibility to be 
transported by the transferrin/transferrin receptor (Tf/TfR) network in place of iron, might 
allow for a natural ruthenium accumulation within cancer cells, typically requiring high iron 
amounts to accommodate for their rapid proliferation (Pessoa et al., 2010; Palermo et al., 
2016). 
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Despite the positive outcomes throughout advanced preclinical and clinical evaluations of 
the anticancer ruthenium(III)-based compounds NAMI-A - the most advanced candidate 
drug having completed Phase II clinical trials - and KP1019, various drawbacks have been 
observed, mainly related to their limited stability in physiological conditions, impairing both 
their general pharmacokinetic and pharmacodynamic profiles (Chen et al., 2007). 
 
 
 
1.6 AziRu: a new organometallic ruthenium complex analogue of NAMI-A 
In 2012, almost concurrently, two different research groups – Walsby et al. (Webb et al., 
2012) and Paduano et al. (Vaccaro et al., 2009; Simeone et al., 2012) – revisited a pyridine 
analogue of NAMI-A, called NAMI-Pyr by the first group and AziRu by the second. In 
comparison with NAMI-A, AziRu has a pyridine ligand replacing the imidazole one, and 
sodium replacing imidazolium as the counterion (Figure 7). 
 
 
 
Figure 7. Molecular structure of AziRu (Mangiapia et al., 2012). 
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NAMI-A and AziRu have great similarities as far as their behavior in aqueous solutions and 
in vitro bioactivity are concerned. In particular, both rapidly replace chloride and DMSO 
ligands with water molecules or hydroxide ions. Biological experiments in vitro have shown 
very low cytotoxicity for AziRu on different cancer cell lines. Although AziRu showed a 
moderate cytotoxicity against human cancer cells, it is interesting to note that its IC50 value 
is half that of NAMI-A towards MCF-7 breast cancer cells (Table 1) (Mangiapia et al., 2012). 
One possible reason for this difference lies in the presence of a pyridine ligand to replace the 
imidazole, giving greater lipophilicity to AziRu, improving cellular uptake efficiency. 
Additionally, the ligands may also play an important role in biomolecular interactions and 
recognition processes. Indeed, hydrophobicity, cellular uptake efficiency and cytotoxic 
effects of anti-proliferative drugs on cancer cells are often strictly correlated. Since the 
AziRu and NAMI-A mechanism of action should be the same, this finding emphasizes the 
importance of the transition-metal complex physical and chemical properties which can play 
a critical role in the vehiculation of the active metal to the molecular targets, thus modulating 
its bioavailability. 
 
 
 
Table 1. IC50 values (µM) relative to NAMI-A and AziRu in the indicate cancer cell lines after 48h of 
incubation (Mangiapia et al., 2012). 
 
 
 
As mentioned above, these Ru(III) compounds behave as valid prodrugs with somehow 
limited side-effects (Dragutan et al., 2015), being likely activated to the more reactive and 
MCF-7 WiDr C6
NAMI-A 620±30
AziRu 305±16 441±20 318±12
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cytotoxic Ru(II) derivatives within the reducing microenvironment of solid tumours (Ravera 
et al., 2004). Furthermore, it has been proposed for Ru(III) complexes that their lower 
toxicity to healthy tissues may be precisely attributed to the so-called “activation by 
reduction” mechanism. 
This kind of mechanism is also shared by other types of compounds (Ravera et al., 2004) 
which, after a reduction, are able to procedure a more active form.  
 
 
 
1.7 The importance of tumour microenvironment and the impact of the immune system 
on tumour progression 
For many years, cancer studies and cancer-related research were focused only on cancer as 
being limited just to cancer cells, ignoring the environment created in the tumour, believing 
it as just a disease characterized by a cell-autonomous process. However, it has been 
acknowledged that tumours are heterogeneous organs, made of a various number of stromal 
components which are crucial players and not just participants in the tumourigenic process. 
One of the interests of cell laboratories is to investigate the role of cancer-associated 
macrophages, tumour-infiltrating lymphocytes (TILs), cancer-associated fibroblasts, and the 
extracellular matrix components that they secrete (Hui and Chen, 2015). Obtaining a much 
better understanding of the usual molecular pathways involved in the interactive bi-
directional communication between tumour components and stroma cells will help 
researchers to manipulate the tumour microenvironment. 
It is known that it contains innate immune cells (including macrophages, neutrophils, mast 
cells, myeloid-derived suppressor cells, dendritic cells, and natural killer cells) and adaptive 
immune cells (T and B lymphocytes) in addition to the cancer cells and their surrounding 
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stroma (which consists of fibroblasts, endothelial cells, pericytes, and mesenchymal cells). 
Numerous epidemiological, clinical and experimental studies shown that tumour 
microenvironment and infiltrating immune cell subsets are important for regulating the 
process of tumour angiogenesis, classical hallmark of cancer onset. These infiltrates involve 
the adaptive immune system including several types of lymphocytes (TILs) as well as cells 
of the innate immunity such as macrophages, neutrophils, eosinophils, mast cells, dendritic 
cells and natural killer cells (Stockmann et al., 2014). Macrophages are specialized 
phagocytes that are able to incorporate invaliding cell debris and microbes as well as to 
secrete different immunomodulatory cytokines. Depending on dynamically changing 
microenvironments that encounter, they have a unique ability to adapt their phenotype. 
Generally, monocytes/macrophages can be polarized to M1 or M2 macrophages (Yang and 
Zhang, 2017; Stockmann et al., 2014). The M1 phenotype, activated by interferon-ɣ and 
microbial products, is characterized as proinflammatory - since produce proinflammatory 
and immunostimulatory cytokines - and is involved in helper T cell (Th) 1 responses to 
infection. M2 macrophages, “alternatively” activated macrophages, exhibit a T-helper-2 
cytokine expression pattern and are considered to be rather immunosuppressive. Although 
most confirmed tumour-promoting cytokines are “M1 cytokines,” TAMs – tumour 
associated macrophages - are considered to have an M2 phenotype (Grivennikov et al., 
2010). Neutrophils represent the largest population of blood leukocytes and are critical for 
the initial inflammatory reaction to invading microbes. They are particularly plentiful in the 
invasive part of the tumour (Bellocq et al., 1998) and neutrophils infiltration has been 
reported in different type of cancer. Moreover, PMN-MDSC population, positive for 
Ly6G+CD11b+ markers, can be found in tumour infiltrate showing tumourigenic activity. 
Some studies demonstrate that, like TAM, CD11b+/Ly6G+ tumour-associated neutrophils 
(TAN) also have differential states of activation/differentiation, suggesting a classification 
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scheme for TAN similar to that of TAM: TAN can thus take an anti-tumourigenic (what we 
are calling an “N1-phenotype”) versus a pro-tumourigenic (“N2”) phenotype (Fridlender et 
al., 2009). Also infiltrates of mast cells have been observed in solid tumours as well as 
hematological malignancies. Mast cells are able to release an array of angiogenic factors, 
including VEGF and fibroblast growth factor (FGF)-2. 
Natural killer cells are cells of the innate immunity characterized by a high cytolytic capacity 
against transformed cancer cells. In addition to their important role in immunosurveillance, 
NK cells can contribute to neovascularization. 
CD4 T cells play essential roles in the function of the immune system. They help B cells 
make antibody, enhance and maintain responses of CD8 T cells, regulate macrophage 
function, orchestrate immune responses against a wide variety of pathogenic 
microorganisms, and regulate/suppress immune responses both to control autoimmunity and 
to adjust the magnitude and persistence of responses. 
CD4 T cells are important mediators of immunologic memory, and when their numbers are 
diminished or their functions are lost, the individual becomes susceptible to a wide range of 
infectious disorders. The initial understanding of the existence of distinctive populations of 
differentiated CD4 T cells came from the analysis of mouse CD4 T cell clones that were 
shown by Mosmann and Coffman (Mosmann et al., 1986) and slightly later by Bottomly and 
her colleagues (Killar et al., 1987) to be divisible into two major groups, designated Th1 and 
Th2 cells by Mosmann and Coffman. Th1 and Th2 clones could be distinguished mainly by 
the cytokines produced by the cells, but also through the expression of different patterns of 
cell surface molecules. About the expression of cytokine, Th1 cells tend to be good IL-2 
producers, and many make TNF-α as well. By contrast, Th2 cells fail to produce IFN-γ or 
lymphotoxin. Their principal cytokines are IL-4, IL-5, and IL-13, but also make TNF-α, and 
some produce IL-9 (Figure 8). 
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Figure 8. Immune suppressive mechanisms of the solid tumor microenvironment. Tumor-derived 
immunosuppressive mechanisms include secreted cytokines and chemokines that recruit and sustain immature 
and suppressive immune cells. These secrete Th2 factors, creating a chronic anti-inflammatory environment 
which promotes and predominates malignant progression (left). NK cell therapy has the potential to reverse 
the anti-inflammation to engender dominant pro-inflammatory signaling through secretion of IFN-γ, Th1 
cytokines, and activation of both innate and adaptive immune cells (right). By elimination of tumor cells and 
immature suppressive cells, NK cells have the potential to reverse the anti-inflammatory signals and eliminate 
tumor progression (Gras Navarro et al., 2015). 
 
 
 
Moreover, other types of CD4 T cells were recognized, such as NKT, but also into Th9 or 
Th17. The latter are mainly observed at the epithelial barriers where they help B and 
epithelial cells to block entrance of pathogens. Another type of CD4 T cells, T regulators 
(Treg), are important in the tolerance and secrete cytokine leading to the inhibition of 
immune cells (Zhu et al., 2010). 
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1.6.1 Regulation of the immune system 
It is known that tumour angiogenesis is critical for tumour development. Although tumour 
cells were first believed to fuel tumour angiogenesis, numerous studies have shown that the 
tumour microenvironment and infiltrating immune cell subsets are important for regulating 
the process of tumour angiogenesis (Stockmann et al., 2014). Besides their known immune 
function, these infiltrating cells are now recognized for their crucial role in regulating the 
formation and the remodeling of blood vessels in the tumour as well as the growth and 
development of tumour. 
Because of their activity, immune system cells could represent a possible target for cancer 
therapy. Many factors can act on the cells of the immune system and therefore interfere with 
the way the immune response functions, such as stress and ageing now consistently appear 
in the literature as factors that act upon the immune system in the way that is often damaging 
(Vitlic et al., 2014). Among these, the EPO can act on macrophages, neutrophils, 
lymphocytes T and B, through a particular receptor. 
The renal cytokine hormone erythropoietin (EPO) regulates bone marrow erythrocyte 
production by stimulating the differentiation and inhibiting the apoptosis of erythroid 
progenitor cells (De Maria et al., 1999; Liu et al., 2006). The production of EPO is controlled 
by a classical feedback loop mechanism and its effects are mediated through the cell surface 
erythropoietin receptors (EpoR). However, EPO also bears extra-hematopoietic properties 
that are transduced by receptors (EpoRs) expressed on various nonerythroid tissues including 
immune cells (Brines and Cerami, 2005; Jelkmann, 2007). Taking into consideration the 
pleiotropic effects of EPO in extraerythroid tissues, the expression of EpoRs on immune 
cells, and the partial similarities between EPO- and cytokine-mediated signal transduction, 
we questioned whether EPO may exert putative immune-modulatory effects, which could 
be of clinical relevance in certain inflammatory diseases. Furthermore, there are provided 
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evidences that EPO acts as a potent anti-inflammatory immune modulator by specifically 
targeting NF-κB p65-driven inflammatory effector pathways (Nairz et al., 2011). 
Few studies have explored in depth the impact of EPO-delivery on the immune system. 
Interestingly, immunosuppressive role of EPO in humans has already been described 
favouring kidney graft survival by decreasing T cell function (Cravedi, 2014). In an auto-
immune encephalomyelitis mouse model, this beneficial effect of EPO was attributed to a 
Th2-polarized immune response. Recently, EPO was described to dampen 
monocyte/macrophage Th1-cytokine production in a DSS-induced colitis, decreasing 
inflammation and disease development (Nairz et al., 2017). On another hand, EPO was 
shown in a mouse model of infection, to inhibit macrophage activation, through NF-κB 
pathway inhibition, impairing antibacterial function (Nairz et al., 2011). Conversely, other 
studies reported improved humoral and cellular immune functions against vaccine antigens 
in CKD patients under ESA supplementation (Cravedi, 2014), which remain unconfirmed 
since then. 
 
 
 
1.6.2 Benefits and drawbacks of using EPO 
The circulating red cell mass reflects a dynamic balance between EPO-regulated red cell 
proliferation and the subsequent loss or destruction of mature erythrocytes. Factors which 
affect oxygen delivery to the kidney, such as the inspired partial pressure of oxygen or 
defective cardio-pulmonary function perturbing normal renal perfusion, can increase EPO 
production and stimulate erythropoiesis. Conversely, increased oxygen supply to the kidney 
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reduces the stimulus to EPO synthesis. The EPO is able to avoid the risk of viral transmission 
and also all the immune reactions. However, even if the EPO is extremely well tolerated, 
some patients can develop anti-EPO neutralizing antibodies.  
Since EPO is the primary hormone responsible for the maintenance of the erythroid lineage, 
anemia - a very common disorder and probably still quite under recognized - may be 
classified based on levels of this hormone present in the circulation, but also according to 
mechanisms such as levels of red blood cell production, destruction, or loss, and by 
parameters of red blood cell morphology, such as the size, color and shape, as well as the 
red blood cell (RBC) indices, mean corpuscular volume (MCV), mean corpuscular 
hemoglobin concentration (MCHC) and mean corpuscular hemoglobin (MCH) (Hodges et 
al., 2007). 
Erythropoietin (EPO), the most widely used erythropoiesis-stimulating agent (ESA), is 
commonly used to promote red blood cell production in the treatment of anemia associated 
with chronic kidney disease (CKD) (Eschbach et al., 1987) and also in cancer-related 
anemia, associated with conventional chemotherapy (Littlewood et al., 2002), even if this 
supportive therapy remains subject of controversy. Indeed, although this condition is 
considered as an independent prognosis factor in various cancers, such as cervical 
carcinoma, head and neck cancer, chronic lymphocytic leukemia and Hodgkin disease, ESAs 
have been reported to further reduce overall survival, increasing cardiovascular and venous 
thromboembolism risks in cancer patients, as well as inducing tumour progression 
independently of the type of cancer or the anti-cancer treatment (Bohlius et al., 2009; Henke 
et al., 2003). 
Mechanisms underlying the role of EPO/ESA on tumour proliferation still remain highly 
controversial. Multiple studies showed that various human tumour cells express EPO-
receptor (EpoR) and respond to EPO stimulation by activating specific signaling pathways 
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and subsequent tumour proliferation (Feldman et al., 2006; Um et al., 2006; Um et al., 2007; 
Henke et al., 2007). However, it has also been claimed that EpoR detection on tumour cells 
is due to commercially unspecific anti-EpoR antibodies and absence of EPO activation on 
tumour cells lacking its receptor has been described (Elliott et al., 2013). Alternatively, 
EPO’s action on tumourigenesis might be mediated, at least in part, by EPO’s role in 
angiogenesis as demonstrated in mouse models (Okazaki et al., 2008), through activation of 
endothelial cells, which is also a matter of debate (Sinclair et al., 2010). 
Keeping in mind what was said before, it was hypothesize that anemia, through both 
endogenous EPO secretion, and exogenous ESA administration constitute bad prognosis 
factor in cancer patients as a consequence of the activation of multiple biological pathways, 
among which the immunological component may be a major one. In this setting, the overall 
project framework of Professeur Hacein-Bey-Abina’s team is the characterization of EPO’s 
treatment impact on the anti-cancer immune response, by using in vivo studies. 
The 4T1 cell line displays multiple interesting features for this project, such as an aggressive 
phenotype, being characterized as triple negative tumour cells, a strong metastasis potential 
similar to human breast cancer (Lelekakis et al., 1999), and the lack of EpoR expression. 
The latter characteristic allows Hacein-Bey-Abina’s team to exclude any direct effect of 
EPO on tumour-cell proliferation or survival. 
They conducted in vivo studies to evaluate the immune suppressive role of EPO in this 
model. For this purpose, 4T1 breast tumour cell lines were intra-dermal injected nearby the 
mammary gland and followed for tumour growth. Mean tumour volume measured every 2 
days was calculated using the following formula: (length × width × thickness)/2. 
Preliminary data showed that EPO-treated mice displayed higher tumour volumes compared 
to control group (Figure 9). 
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Figure 9. Impact of EPO on tumour establishment and development. Tumour size was measured by a caliper 
and the volume estimated using the following formula, V=length*Width2/2. Values are expressed as the mean 
+/- SEM of 2 independent experiments, n=14 mice per group. Statistics: unpaired t test, *p<0.05, **p<0.01, 
***<0.001. 
 
 
 
Moreover, to gain further insight into the mechanisms involved in the tumourigenic EPO 
effect, the same team analyzed the infiltration and the activation status of immune cells at 
the primary tumour site. Interestingly, results showed that the proportion of TIL decreased 
over time more dramatically in EPO-treated mice as compared to PBS-treated control mice, 
from D10 to D16 pi, with a higher impact on CD4 T helper cells (CD4 Th) than on CD8 T 
cells (Figure 10). These differences are maintained throughout the analysis of intra-tumour 
immune infiltrate. 
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Figure 10. Impact of EPO on TIL proportion. Tumour-infiltrating immune cells were purified using 
Histopaque gradient and then incubated with specific antibodies -CD16-32, -CD45-PE, -CD3-BV785, 
-CD4-BV421, -CD8 -AF700, during 30 min at 4°C before flow cytometry acquisition (Fortessa). Data 
are analysed on FlowJo.10. Values are expressed as mean +/- SEM of 3 independent experiments, n=15 mice 
per group. Statistics: unpaired t test, *p<0.05, **p<0.01, ***<0.001. 
 
 
 
Blood analysis revealed comparable kinetics of T cell concentrations between EPO- and 
PBS-treated mice indicating that EPO effect is not attributable to a systemic action but rather 
associated to an inhibition of T-cell recruitment within the tumour site. In order to analyze 
deeply the effect of EPO on adaptive immune response initiation, the team has planned to 
characterize T-cell activation in draining lymph nodes and polarization toward effector T 
cell subsets. The same analysis has been also planned for TIL. 
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INNOVATIVE DRUG DELIVERY SYSTEM 
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The use of pharmaceutical technologies can be an astute choice for developing innovative 
therapeutic strategies. The association of nanotechnologies provides new therapeutic 
possibilities due to the combined properties of different skills. Nanocarriers can localize the 
drugs administration to the specific target tissue. In addition, drugs encapsulated within or 
conjugated to nanoparticle vehicles display pharmacokinetics that are markedly different 
from those of free drugs, in fact nanocarriers can provide additional drug sustained release 
or different pharmacokinetic and bio distribution profiles, improving the drug therapeutic 
index. Furthermore, they could facilitate the passive targeting as well as the active one, 
leading to less side effects. 
Liposomes, micelles, liquid and solid lipid nanocapsules, polymeric nanoparticles, 
dendrimers, and fullerenes are all nanotechnologies which have been recently assessed for 
medical applications, such as cancer therapy, anesthesia, the treatment of cutaneous and 
infectious diseases, the administration of antidepressants, and the treatment of unexpected 
diseases, such as alopecia. Among all, liposomes are the most commonly used vehicles, and 
most of the currently approved nanoparticle chemotherapy formulations are liposomal (Lee 
et al., 2017). 
 
 
 
2.1 Drug delivery strategies by using nucleolipidic nanovectors 
Nucleolipids - hybrid molecules carrying lipid moieties covalently attached to nucleoside 
scaffolds - have recently attracted great interest, in both the design of artificial molecular 
devices (Mao et al., 2000; Petitjean et al., 2004; Rosemeyer et al., 2005) and the development 
of novel therapeutic agents. (Krutzfeldt et al., 2005) In contrast to classical amphiphiles, 
nucleolipids possess a highly informative polar headgroup (adenine, thymine, guanine, 
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uracil, or related analogs) with additional H-bonding and p-stacking capacity allowing them 
to enhance their self-aggregation properties and specifically recognize other nucleobases 
(Barthelemy et al., 2005; Onda et al., 1996). 
Nanostructuring in pseudo-physiological conditions leads to efficient cellular uptake 
through the phospholipid bilayers as well as confers protection to the drug from extracellular 
enzymatic degradation. On the other hand, full reversibility—within the cells—of the 
chemical bonds connecting the nucleoside decorations may be a powerful strategy to prevent 
toxicity, thus opening the way to a completely new approach for drug delivery. 
As mentioned before, even if our low molecular weight Ru complex – AziRu – is more 
effective that the well-known NAMI-A, it presents some limitations, in particular due to its 
low stability in physiological environment, in which it can be converted in non-soluble poly-
oxo species. Although the formation of poly-oxo species does not seem to significantly 
hamper the ruthenium bioactivity, at least when tested on some tumour cell lines, an 
important consequence of these degradation processes is that only a limited amount of the 
administered drug can be effectively internalized into cells (Sava et al., 1999). Therefore, 
aiming at improving the stability of the ruthenium(III)-based drugs in biological 
environment, as well as their suitability for biomedical applications, an innovative strategy 
for their transport in vivo by means of nanobiotechnological tools has recently proposed. In 
detail, the project is based on the incorporation of AziRu, (Simeone et al., 2011; 
Montesarchio et al., 2013) used as a core molecular scaffold - into suitable nucleolipidic 
structures, developing a mini-library of highly functionalized amphiphilic ruthenium(III) 
complexes, including differently decorated nucleolipids (Figure 11). In particular, three 
different types of nucleolipids are used: 
- ToThy : 3- [4-pyridylmethyl] -30-O-oleoyl-50-O (monomethoxy) triethylene glycol-acetyl-
thymidine; 
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- HoThy : 3- [4-pyridylmethyl] -30-O-oleyl-50-O (benzyloxy) exaetilen glycol-acetyl-
thymidine; 
- DoHu : 3- [4-pyridylmethyl] 20, 30 of O-oleyl-50-O (benzyloxy) esaetilen glycol-acetyl-
uridine 
In these structures, the active metal part -AziRu - was attached to the nucleobase of a 
nucleoside, which was further decorated with one or two long aliphatic chains able to 
promote the assembly into ordered nanosized aggregates in aqueous solutions and with one 
oligoethylene glycol chain of variable length, behave as a protective “stealth” agent for the 
nanoaggregates (Vaccaro et al., 2009; Lasic et al., 1991). 
 
 
 
Figure 11. Molecular structures of Ru(III)-containing complexes. The investigated Ru(III) nucleolipidic 
complexes (A) ToThyRu, (B) HoThyRu and (C) DoHuRu, along with the low molecular weight Ru(III) 
complex (D) AziRu (Mangiapia et al., 2012). 
 
 
 
The resulting nucleolipidic Ru(III) complexes - named ToThyRu, HoThyRu and DoHuRu- 
are endowed with a marked propensity for self-aggregation in physiological solutions and 
45 
 
high in vitro antiproliferative activity against human cancer cells, thus proving to be 
promising lead compounds for future in vivo studies (Irace et al., 2017). 
However, knowing that cholesterol (fundamental constituent of organism) plays a critic role 
in keeping the fluidity of the cell membrane as well as the endocytosis phenomena, Paduano 
and co-workers focused on the design of bio-mimetic model membranes system that, 
exploiting the advantages of the similarity to the biological membranes, could be a new 
strategy for the drug delivery. Thus, the inclusion of cholesterol in membrane models can 
have different advantages. It increases the rigidity of the lipid bilayer and reduces its 
instability in the blood, due to the serum protein binding (Mabrey et al., 1978). Furthermore, 
recognized by receptors of low-density lipoprotein (LDL), it can facilitate the endocytosis 
(Krieg et al., 1993). In this context, a ruthenium complex, covalently linked to a cholesterol-
containing nucleolipid and stabilized by co-aggregation with a biocompatible lipid, has been 
synthetized. The amphiphilic ruthenium complex, named ToThyCholRu, is intrinsically 
negatively charged and has been inserted into liposomes formed by the cationic 1,2-dioleyl-
3-trimethylammoniumpropane chloride (DOTAP) to hinder the degradation kinetics 
typically observed for known ruthenium-based antineoplastic agents (Figure 12). These 
nanovectors, containing up to 30% in moles of the ruthenium complex and stable for several 
weeks, revealed an important antiproliferative activity and, most remarkably, the highest 
ability in ruthenium vectorization measured so far (by in vitro bioactivity experiments) and 
fast cellular uptake in human carcinoma cells (by fluorescence microscopy experiments - 
following the incorporation of rhodamine-B within the ruthenium-loaded liposomes). 
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Figure 12. Molecular structure of the nucleolipid ToThyCholRu (Simeone et al., 2012). 
 
 
 
In the first series of compounds developed, the pyridine residue – chosen as the privileged 
ligand for ruthenium – was anchored to the N-3 position of the pyrimidine part. Therefore, 
in order to take advantage of the recognition abilities of the nucleobases and their potential 
interactions with nucleic acids via Watson–Crick hydrogen bonds or stacking contacts, these 
should not be blocked by hindered groups. Then, based on the promising results obtained for 
the first generation of ruthenium(III) complexes, Paduano and co-workers have designed a 
novel nucleolipid where the pyridine ligand is not attached at the N-3 but at the C-3′ position 
on the sugar, identified as a model compound for a second generation of metal-complexed 
nucleolipids (Montesarchio et al., 2013). 
This compound, named HoUrRu, has an oleic acid residue at the 2′-position and a heptakis 
(ethylene glycol) chain at the 5′- position. The peculiarity of this compound is in the presence 
of the pyridine in the 3′-position (Figure 13), but with preservation of the same decoration 
present in HoThyRu. All three linked groups – the pyridine moiety and the hydrophilic and 
the lipophilic chains – are linked to the sugar, so the uracil nucleobase is not hampered in 
hydrogen-bond formation or in stacking interactions with potential in vivo targets. 
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Figure 13. Molecular structure of nucleolipidic ruthenium(III) complex (Bn = benzyl) (Montesarchio et al., 
2013). 
 
 
 
It is interesting to highlights that, with respect to other amphiphilic Ru-complexes previously 
investigated, HoUrRu exhibited enhanced capability to co-aggregate with different lipids. In 
vitro bioactivity assays showed (when it’s co-aggregated with POPC or DOTAP) a much 
more inhibition of the human cancer cells MCF-7 and WiDr growth, respect to the reference 
ruthenium-complex AziRu. Furthermore, compared with previously synthesized analogs 
HoThyRu, ToThyRu and DoHuRu, HoUrRu showed similar antiproliferative ability on 
MCF-7 cells - with IC50 values in the 10 μM range - and notably, a higher impact on WiDr 
cells, with IC50 values in the 10–20 μM range (Figure 14; Table 2) (Montesarchio et al., 
2013). 
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Figure 14. Cell survival index values, evaluated by MTT assay and total cell count, in MCF-7 and WiDr cell 
lines incubated for 48h with a range of concentrations (10 → 100 μM) of the different Ru-containing 
formulations and with HoUrRu and AziRu, as indicated in the legend. AziRu, a NAMI-A analog, is here used 
as a reference drug (Montesarchio et al., 2013). 
 
 
 
 
 
Table 2. IC50 values (μM) in the indicated cell lines following 48 h of incubation with cisplatin (CDDP), 
NAMI-A, Azi-Ru and with POPC or DOTAP (in parentheses) formulations of DoHuRu, HoThyRu, ToThyRu 
and HoUrRu (in bold) amphiphilic ruthenium-complexes (Montesarchio et al., 2013). 
 
 
 
So, based on the amazing results obtained, there are many benefits related to the use of 
nanostructures in metal-based drug delivery, including the potential to transport greater 
amounts of the metal in the bloodstream, to obtain “stealth” aggregates to produce 
aggregates selectively captured by specific cancer cell lines by inserting, within the 
aggregates, targeting molecules specifically recognized by receptors overexpressed in 
tumour cells (Mangiapia et al., 2012). 
 
 
 
Cell lines CDDP NAMI-A Azi-Ru
MCF-7 25 ± 3 620 ± 30 305 ± 16 71 ± 6 (13 ± 5) 7 ± 4 (15 ± 7) 9 ± 4 (19 ± 8) 14 ± 7 (8 ± 5)
WiDr — — 441 ± 20 99 ± 5 (41 ± 10) 40 ± 5 (65 ± 8) 75 ± 4 (50 ± 11) 20 ± 8 (12 ± 5)
DoHuRu POPC 
(DOTAP)
HoThyRu POPC 
(DOTAP)
ToThyRu POPC 
(DOTAP)
HoUrRu POPC 
(DOTAP)
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2.2 Co-aggregation with biocompatible lipids 
Nucleolipids have been selected as scaffold for building up the amphiphilic Ru complexes 
because of their capability to mime the molecular organizations of the biological systems, as 
well as for the possibility to form a wide variety of supramolecular systems such as 
liposomes/vesicles, cubic phases, ribbons, etc. (Barthelemy et al., 2009; Fortini et al., 2004), 
that have found an increasing application in the biomedical field.  
However, as NAMI-A and “naked” AziRu, these amphiphilic ruthenium-complexes 
described, when left in aqueous solutions, also tend to be unstable, forming insoluble 
precipitates in a period ranging from few hours, in phosphate buffer, to a few days, when 
dissolved in pure water. 
For that reason, besides enhancing their biostability as well as aiming at biocompatible 
systems, these nucleolipidic complexes are also co-aggregated with biocompatible lipids, 
giving rise to stable and biomimetic ruthenium-based nanoaggregates acting as efficient 
nanovectors. These nanoaggregates - which have been subjected to an in-depth 
microstructural characterization - are ad hoc designed to present high stability in aqueous 
condition as well as to transport high ruthenium amounts in cells, thereby ensuring more 
effective metal-based treatments. Nucleolipids, being amphiphilic compounds, offer unique 
properties of spontaneous self-assembly providing nano-sized nanoaggregates with exquisite 
tunability in terms of volume and shape (Lainé et al., 2012; Licona et al., 2017). 
 
 
 
2.2.1 Zwitterionic lipid POPC 
The synthesized molecules have been studied as pure aggregates, as well as in mixture with 
palmitoyl-2-oleoyl-sn-glycero-3- phosphocholine (POPC) (Mangiapia et al., 2012), at 
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selected POPC/Ru molar ratios (85:15). Indeed, the combination of Ru complexes with 
phospholipids can allow a fine tuning of the metal amount to be administered, as well as 
protection from degradation, since the ruthenium complex is stuck in the liposome bilayer. 
Among phospholipids, POPC (its structure is shown below) is of particular interest because 
it is one of the components of natural membranes (Arriaga et al., 2009). 
 
 
 
 
 
The aggregation behavior of the prepared nanoaggregates has been investigated through an 
experimental strategy that combines dynamic light scattering (DLS) to estimate aggregate 
dimensions, small angle neutron scattering (SANS) to analyze the aggregate morphology 
and to determine their geometrical characteristics, and electron paramagnetic resonance 
(EPR) to get information on the dynamics of the lipid hydrophobic tail in the bilayer. The 
evaluation of the “cell survival index” emerging from concentration/effect curves, suggested 
that these nanocarriers produce a cytotoxic effect substantially similar to that of the “naked” 
AziRu, although they enclose only 15% of ruthenium in moles. They exhibited IC50 values 
much lower (∼6 times) than AziRu (Table 3) and other known organometallic complexes, 
but on the other hand, they required quite long times (>6 h) to produce relevant cytotoxic 
effects, probably as a consequence of their slow cell uptake (Mangiapia et al., 2012). 
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Table 3. IC50 values relative to NAMI-A, AziRu and to the effective ruthenium concentration carried by 
ToThyRu/POPC, HoThyRu/POPC and DoHuRu/POPC liposomes in the indicated cell lines after 48 h of 
incubation (MCF-7: human breast adenocarcinoma cell line. WiDr: human epithelial colorectal 
adenocarcinoma cell line. C6: tumour rat glioma cells) (Mangiapia et al., 2012). 
 
 
 
2.2.2 Cationic lipid DOTAP 
In order to enhance the antineoplastic activity, by increasing the ruthenium content within 
the aggregates and favoring their cell uptake, the coaggregation of the nucleolipids whit the 
cationic lipid 1,2-dioleyl-3- trimethylammoniumpropane chloride (DOTAP) (shown below) 
in the mixture 50:50 has been tested. 
 
 
 
 
 
The resulting nanoaggregates are specifically designed to present high stability in biological 
environment even at high Ru-complex content. The aggregation behavior of the prepared 
nanoaggregates, as well as their stability in the time, has been investigated through dynamic 
MCF-7 WiDr C6
NAMI 620 ± 30
AziRu 305 ± 16 441 ± 20 318 ± 12
DoHuRu/POPC 71 ± 6 99 ± 5 24 ± 5
HoThyRu/POPC 7 ± 4 40 ± 5 81 ± 7
ToThyRu/POPC 9 ± 4 75 ± 4 36 ± 8
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light scattering (DLS) to estimate aggregate dimensions, small angle neutron scattering 
(SANS) to analyze the aggregate morphology and to determine their geometrical 
characteristics, neutron reflectivity and zeta potential to gain structural information on the 
bilayer, and electron paramagnetic resonance (EPR) to get information on the dynamics of 
lipid hydrophobic tails in the bilayer.  
Based on the IC50 values (Table 4), the three mixed amphiphilic ruthenium 
complexes/DOTAP nanoaggregates are much more active than the precursor AziRu and also 
than the analogues nanoaggregates via POPC, perhaps due to their faster cellular up-take, 
that results massive after only 3h (Montesarchio et al., 2013). 
 
 
 
Table 4. IC50 values relative to AziRu and to the effective ruthenium concentration carried by 
ToThyRu/DOTAP, HoThyRu/DOTAP and DoHuRu/DOTAP liposomes in the indicated cell lines after 48 h 
of incubation. IC50 values are reported as means ± SEM. (MCF-7: human breast adenocarcinoma cell line. 
WiDr: human epithelial colorectal adenocarcinoma cell line. C6: tumour rat glioma cells.) (Montesarchio et 
al., 2013). 
 
 
 
The cationic liposomes are emerged as valid alternative to the neutral vesicles, and could 
bring different benefits, such as the major interaction with the cell membranes (Wiethoff et 
al., 2001). 
MCF-7 WiDr C6
AziRu 305 ± 16 441 ± 20 318 ± 12
ToThyRu/DOTAP 19 ± 8 50 ± 11 54 ± 8
HoThyRu/DOTAP 15 ± 7 65 ± 8 43 ± 11
DoHuRu/DOTAP 13 ± 5 41 ± 10 34 ± 9
IC50 [μM]
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The positive charge can also enhance the aggregation with the negative one of the 
nucleolipids forming the amphiphilic ruthenium complex and thus make a more stable 
liposome (Figure 15). 
 
 
 
Figure 15. Representation of the amphiphilic ruthenium complex/DOTAP nanoaggregates (Mangiapia et al., 
2013). 
 
 
 
2.3 Up-take investigations 
Because transition metal-based anticancer drugs target DNA in the nuclear cage, the cellular 
uptake characteristics and the nuclear entry ability have emerged as central factors 
influencing their antiproliferative efficacy. Thus, in order to evaluate the kinetics of cellular 
up-take as well as the investigation of the mechanism of action of the synthesized Ru(III) 
complexes, experiments of fluorescent microscopy were carried out into human MCF-7 
cancer cells, by using the fluorescent probes Rhodamine B lipid derivative, 1,2- dioleoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium salt - 
inserted in the liposomal bilayer of DoHuRu/DOTAP - and fluorogenic group of the dansyl 
– linked to HoThyRu for deeper studying the cell internalization process and metabolic fate. 
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Thus, the new nucleolipidic Ru(III) complex, named HoThyDansRu, was synthesized. It 
contains the dansyl group attached through a sulfate bridge in the 2′-position, an oleic acid 
residue at the 3′-position, an ethylene glycol chain in the 5′-position and a pyridinylmethyl 
arm at N-3 (Figure 16). 
 
 
 
Figure 16. Chemical structure of the fluorescently labelled ruthenium(III) complex HoThyDansRu (Bn = 
benzyl) (Mangiapia et al., 2013). 
 
 
 
About the cell uptake, the fluorescent microphotographs (Figure 17), showed a high 
propensity of DoHuRu/DOTAP liposomes to cross cell membranes, and the cell entry 
appears to be a very fast process (Mangiapia et al., 2013). Furthermore, merged images - 
where fluorophore emission is overlapped at the same location - suggest also a nuclear 
localization of the aggregates. By means of their lipid properties, it is feasible that the Ru 
complexes/DOTAP nanoaggregates are taken up by cells directly via membrane fusion and 
by endocytosis. 
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Figure 17. Fluorescent microphotographs of monolayers showing the cellular uptake of liposomes by human 
MCF-7 breast adenocarcinoma cells. MCF-7 were incubated with 100 μM of the rhodamine-added 
DoHuRu/DOTAP liposome solution for 30 min, 1 h, and 3 h. DAPI is used as a nuclear stain (shown in blue). 
Rhodamine-dependent fluorescence (Rhod) of DoHuRu/DOTAP liposomes is shown in green. In merged 
images (Merge), the two fluorescent emissions are overlapped (Mangiapia et al., 2013). 
 
 
 
On the other hand, to assess the fate of the active ruthenium complex, additional in vitro 
fluorescence experiments were performed on MCF-7 cells treated with the dansyl-labeled 
ruthenium complex HoThyDansRu co-aggregated with DOTAP. In this way, fluorescently 
labeled HoThyDansRu (Figure 18) localizes rapidly within the cells. The analysis of 
fluorescent emission also suggests that the complexes lodged in DOTAP liposomes enter the 
cytoplasm before being predominantly delivered to discrete foci in the perinuclear 
compartment; moreover, although attenuated by DAPI nuclear staining, dansyl-dependent 
fluorescence emission is also detectable in the nuclei area. Overall, in addition to 
demonstrating an effective process of cellular uptake, the fluorescent patterns seem to 
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suggest an intracellular liposome degradation coupled with the release of the 
pharmacologically active agent within the cytoplasm. This would explain the prevalent 
rhodamine-associated fluorescence and the concomitant generation of discrete dansyl-
associated spots following cellular uptake and disaggregation of nanocarriers. 
 
 
 
Figure 18. Fluorescent microphotographs of monolayers showing the cellular location of dansylated- 
HoThyDansRu complex into human MCF-7 breast adenocarcinoma cells subsequent to nanocarriers 
application. MCF-7 were incubated with 100 μM of the intrinsically fluorescent HoThyDansRu/DOTAP 
liposome solution for 30 min, 1 h, and 3 h. DAPI is used as a nuclear stain (shown in blue). Dansyl dependent 
fluorescence (Dans) of HoThyDansRu/DOTAP liposomes is shown in red. In merged images (Merge), the two 
fluorescent emissions are overlapped (Mangiapia et al., 2013). 
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AIM OF THE PROJECT 
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This proposal is part of a broader multidisciplinary research project aimed at the 
development of biocompatible and stable amphiphilic molecules containing Ru(III) 
complexes, assembled in selective nanostructures able to improve their efficacy and 
bioavailability with respect to the well-known NAMI complex, already under clinical trial. 
The interest toward ruthenium arises from its promising anticancer properties as reported in 
literature by others and our research team, showing the high antiproliferative activity of 
novel Ru-complexes. At this stage we have tested the amphiphilic nucleolipid ruthenium-
based complexes (named ToThyRu, HoThyRu and DoHuRu), which contain the low 
molecular weight complex AziRu as "active metal part", and which are co-aggregated with 
the lipids POPC (1-palmitoil-2oleoil-sn-glycero-3fosfocolina) and DOTAP (N- [1- (2,3-
dioleoilossi) propyl] -N, N, N-trimetilammonio methyl-sulfate) (Mangiapia et a., 2013; 
Vitiello et al., 2015). The evaluation of the biological activity of Ru-based complexes is 
achieved by means of in vitro experimental models of human tumours and metastases of 
different histological origin. As well, the in vitro bioactivity profile toward healthy cells will 
be also assessed in order to establish the biocompatibility of the compounds under testing. 
The used human tumour cell lines - characterized by different metastatic potential and 
cultured according to the ATCC (American Type Culture Collection) procedures - are 
included in the cellular lines panel of the National Cancer Institute (USA) for the 
bioscreening of the antitumour and antimetastatic effects. 
Many different ruthenium compounds have been recently tested for their anticancer 
properties, without enough investigations into both their mode of action at cellular level and 
their mechanism of action at the molecular level. In this frame, given that the identification 
of the exact mode of action is critical not only for drug classification but also for the rational 
design of new compounds with enhanced properties, an important goal of this work is to 
deeper elucidate the molecular mechanisms of action of ruthenium in cancer cells, giving 
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more insights about the activated cell death pathways as well as the main molecular 
biological targets involved through a series of in vitro bioscreens. In particular, by focusing 
on well-established breast cancer cell lines as in vitro models for human mammary tumours 
(such as the endocrine-responsive (ER) breast adenocarcinoma MCF-7 and the triple-
negative breast adenocarcinoma (TNBC) MDA-MB-231 cell models, together with their 
variants CG5, MDA-MB-436 and MDA-MB-468), we report via preclinical bioscreens how 
ruthenium complexes administration can activate specific molecular cell death pathways, 
thereby interfering with cancer cells growth and proliferation.  
In addition, given the importance of tumour microenvironment for the efficacy of the most 
common anticancer therapy, as for the Ru(III) complexes (because of their “activation by 
reduction”), and considering that the microenvironment is rich in immune adaptive cells, a 
further study of this work, realized in collaboration with the clinical immunology laboratory 
at the faculty of Pharmacy in Paris, concerns the role of EPO on extra-erythroid components 
- such as immune system cells - and the evaluation of exogenous EPO administration impact 
on tumour intake/growth and on tumour immune environment in the 4T1 mouse mammary 
carcinoma cells transplanted into Balb/c female mice. In this respect, some studies have 
shown that EPO might promote tumour proliferation both in vitro on primary or cell lines 
and in vivo models, whereas other show an absence of a direct action on tumours. Otherwise, 
EPO’s action on tumorigenesis might be mediated, at least in part, by EPO’s role in 
angiogenesis as demonstrated in mouse models, through activation of endothelial cells, 
which is also a matter of debate. 
Furthermore, recent studies have explored in depth the impact of EPO-delivery on the 
immune system. EPO receptors expression at the mRNA level has already been 
demonstrated in T cells, B cells and macrophages in several species, including human. 
Despite huge efforts and years of research spent on both clinical and experimental model 
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development, neither mechanisms underlying the increase in tumour progression nor the 
markers of susceptibility have been identified. However, the individual EPO susceptibility 
might modulate immunity and impact tumour surveillance.  
Giving that CD11b+Ly6G+ tumour-infiltrating lymphocytes population is decreased in EPO-
treated mice, as described before, in order to evaluate the gene expression profiles by RT-
qPCR on FACS-sorted and to discriminate between the anti-tumourigenic (such as IL-12, 
TNF𝛼 , ICAM1), and the pro-tumourigenic (such as Arginase 1, iNOS, MMP9, CCL3) 
phenotypes, as well as to classify the different polarization of the adaptive immune cells, 
such as CD4 (Th1, Th2, Th17 or Treg), 4T1 breast tumour cells were intra-dermal injected 
nearby the mammary gland of Balb/c female mice. 
In addition, a further step of this study is focused on the determination of cytokine and 
chemokine profiles induced by EPO in the tumour microenvironment and peripheral blood 
as well as in draying lymph nodes. Identifying the most relevant source of immune 
suppressive factors (such as TGF-β and IL-17) produced by immune cells and/or tumour 
cells themselves could be an important step in the characterization of the cascade of events 
underling the EPO tolerogenic effect. To this aim, a large panel of cytokines and chemokines 
has been analyzed in purified tumour-associated immune cells as well as in serum of tumour-
bearing mice. In this setting, the levels of the main Th1-, Th2-, Th17- and Treg-derived 
cytokines as well as chemokines known for their neutrophil attraction potential has been 
analyzed by Cytometric Bead Array or ELISA. 
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MATERIALS AND METHODS 
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4.1 Cell cultures 
Human cancer cell lines have been a useful tool for the study of the genetics, molecular 
biology, biology, and therapy of cancer in many tumor types, including breast cancer 
(Chavez et al., 2010). 
Human breast adenocarcinoma cells, epithelial-like type as MCF-7, CG-5, MDA-MB-231 
and MDA-MB-468 lines, and pleomorphic-like type as MDA-MB-436 line, were grown in 
DMEM (Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (FBS, 
Cambrex, Verviers, Belgium), L-glutamine (2 mM, Sigma, Milan, Italy), penicillin (100 
units/ml, Sigma) and streptomycin (100 μg/ml, Sigma), and cultured in a humidified 5% 
carbon dioxide atmosphere at 37°C, according to ATCC recommendations. MCF-7 and CG-
5 are endocrine-responsive (ER) breast cancers; MDA-MB-231, MDA-MB-468 and MDA-
MB-436 are triple-negative breast cancers (TNBC) (Lacroix et al., 2004; Holliday et al., 
2011). Human HaCaT keratinocytes and rat L6 skeletal muscle cells, used as healthy control 
cell lines, were grown in the same experimental conditions. 
- MCF-7 cells, (HTB-22, ATCC), human breast adenocarcinoma cells isolated from a 
69-year-old Caucasian woman. Initially they are distributed in monolayer ("Cell 
Biology" ATCC protocol) retaining several characteristics of differentiated 
mammary epithelium including ability to process estradiol via cytoplasmic estrogen 
receptors and the capability of forming domes. Their growth is inhibited by the tumor 
necrosis factor alpha (TNF α). The cells express the WNT7B oncogene. 
- CG-5 cells, derived from a casual contamination by MCF-7 cells of a primary culture 
from a pleural effusion of a patient with postmenopausal advanced breast cancer, a 
generous gift from Dr Sica (Institute of General Histology and Embryology, Catholic 
University “Sacro Cuore”, Rome, Italy) (Natoli et al., 1983). The characterization of 
this MCF-7 variant revealed chromosomal properties highly similar and alloenzyme 
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phenotypes identical to those of MCF-7 cells. However, CG-5 cells contain higher 
concentrations of steroid receptors and are more sensitive to the proliferative effect 
of estrogens than MCF-7 cells (Badino et al., 1996). 
- MDA-MB-231 cells, are aneuploid female, with chromosome counts in the near-
triploid range. Normal chromosomes N8 and N15 were absent. Eleven stable 
rearranged marker chromosomes are noted as well as unassignable chromosomes in 
addition to the majority of autosomes that are trisomic (ATCC HTB-26). Many of 
the marker chromosomes are identical to those shown in the karyotype reported by 
Satya-Prakash and coworkers (Satya-Prakash et al., 1981). MDA-MB-231 cells 
present a precise spectrum of proteolytic activities; they are also characterized by a 
relatively rare steroid receptor status (two of them are estrogen receptor-negative 
(ER−)/progesterone receptor-positive (PgR+), the third is ER+/PgR−) (Lacroix et al., 
2004). 
- MDA-MB-468 cells, were isolated in 1977 by Cailleau et al., from a 51-year-old 
female patient with metastatic adenocarcinoma of the breast, and is commonly used 
in cancer research (Cailleau et al., 1978). These cells were extracted from pleural 
effusion of mammary gland and breast tissue, and have proven useful for the study 
of metastasis, migration and invasion of breast cancer (ATCC HTB-132). MDA-468, 
is a breast cancer cell line with a very high number of EGF receptors and is growth-
inhibited at EGF concentrations, that stimulate most other cells (Filmus et al., 1985). 
- MDA-MB-436, breast cancer cell line was first derived from pleural fluid obtained 
from a 43-year-old breast cancer Caucasian patient in 1976. MDA-MB-436 is 
pleomorphic with multinucleated component cells and reacts intensely with anti-
tubulin antibody. In vitro, the MDA-MB-436 cell line has abundant activity in both 
the Boyden chamber chemo invasion and chemotaxis assay (ATCC HTB-130).  
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4.2 Synthesis of the ruthenium complexes ToThyRu, HoThyRu and DoHuRu and 
preparation of the lipid-based nanoaggregates 
The ruthenium complexes investigated, ToThyRu, HoThyRu and DoHuRu were prepared 
by reacting in stoichiometric amounts the starting nucleolipids, named ToThy, HoThy or 
DoHu (Simeone et al, 2011) with the Ru complex [trans-RuCl4(DMSO)2]−Na+ following a 
previously described procedure (Mangiapia et al., 2012). All the synthetic intermediates and 
the final nucleolipidic Ru(III) complexes were obtained in a pure form and characterized by 
ESI-MS and NMR analysis in order to confirm their identity. Remarkably, the signals in the 
1H NMR spectra of the nucleolipid-based Ru(III) complexes are particularly diagnostic of 
the effective complex formation (Velders et al., 2004). Detailed microstructural 
characterization of these nucleolipidic complexes was carried out in pure water and in a 
pseudo-physiological solution, through an experimental strategy combining small-angle 
neutron scattering (SANS) to analyze the aggregate morphology as well as to determine their 
geometrical characteristics, dynamic light scattering (DLS) to estimate aggregate 
dimensions and electron paramagnetic resonance (EPR) to provide information on the 
dynamics of the lipid hydrophobic tail in the bilayer. Furthermore, biological validation of 
these nanocarriers was carried out by studying their cytotoxicity profiles on a panel of 
different human and non-human cell lines (Riccardi et al., 2017). 
 
 
 
4.3 In vitro bioscreens 
The anticancer activity of ruthenium-containing nucleolipidic nanoparticles and of AziRu 
was investigated through the estimation of a “cell survival index”, arising from the 
combination of cell viability evaluation with cell counting (Mangiapia et al., 2012). More 
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specifically, the cell survival index is calculated as the arithmetic mean between the 
percentage values derived from the MTT assay and the automated cell count, providing a 
more accurate parameter of the concrete number of cells that survive after a preclinical in 
vitro study (Irace et al., 2017). Cells were inoculated in 96-microwell culture plates at a 
density of 104 cells/well, and allowed to grow for 24 h. The medium was then replaced with 
fresh medium and cells were treated for further 48 h with a range of concentrations (1 → 
1000 μM) of AziRu, and of ToThyRu and DoHuRu complexes lodged either in POPC or 
DOTAP liposomes (ToThyRu/POPC and ToThyRu/DOTAP, DoHuRu/POPC and 
DoHuRu/DOTAP, respectively). Using the same experimental procedure, cell cultures were 
also incubated with ruthenium-free ToThy/POPC, ToThy/DOTAP, DoHu/POPC and 
DoHu/DOTAP liposomes as negative controls, as well as with cisplatin (cDDP) - a positive 
control for cytotoxic effects. Cell viability was evaluated using the MTT assay procedure, 
which measures the level of mitochondrial dehydrogenase activity using the yellow 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma) as substrate. 
The assay is based on the redox ability of living mitochondria to convert dissolved MTT into 
insoluble purple formazan. Briefly, after the treatments, the medium was removed and the 
cells were incubated with 20 μl/well of a MTT solution (5 mg/ml) for 1 h in a humidified 
5% CO2 incubator at 37 °C. The incubation was stopped by removing the MTT solution and 
by adding 100 μl/well of DMSO to solubilize the obtained formazan. Finally, the absorbance 
was monitored at 550 nm using a microplate reader (iMark microplate reader, Bio-Rad, 
Milan, Italy). Cell number was determined by TC10 automated cell counter (Bio-Rad, Milan, 
Italy), providing an accurate and reproducible total count of cells and a live/dead ratio in one 
step by a specific dye (trypan blue) exclusion assay. Bio-Rad’s TC10 automated cell counter 
uses disposable slides, TC10 trypan blue dye (0.4% trypan blue dye w/v in 0.81% sodium 
chloride and 0.06% potassium phosphate dibasic solution) and a CCD camera to count cells 
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based on the analyses of captured images. Once the loaded slide is inserted into the slide 
port, the TC10 automatically focuses on the cells, detects the presence of trypan blue dye 
and provides the count. When cells are damaged or dead, trypan blue can enter the cell 
allowing living cells to be counted. Operationally, after treatments in 96-microwell culture 
plates, the medium was removed and the cells were collected. Ten microliters of cell 
suspension, mixed with 0.4% trypan blue solution at 1:1 ratio, were loaded into the chambers 
of disposable slides. The results are expressed in terms of total cell count (number of cells 
per ml). If trypan blue is detected, the instrument also accounts for the dilution and shows 
live cell count and percent viability. Total counts and live/dead ratio from random samples 
for each cell line were subjected to comparisons with manual hemocytometers in control 
experiments. The calculation of the concentration required to inhibit the net increase in the 
cell number and viability by 50% (IC50) is based on plots of data (n = 6 for each experiment) 
and repeated five times (total n = 30). IC50 values were obtained by means of a concentration 
response curve by nonlinear regression using a curve fitting program, GraphPad Prism 5.0, 
and are expressed as mean values ± SEM (n = 30) of five independent experiments. 
 
 
 
4.4 Cell morphology 
Human breast cancer cell lines were grown on 60 mm culture dishes by plating 5 × 105 cells. 
After reaching the subconfluence, cells were incubated for 48 h with IC50 concentrations of 
the ruthenium-containing liposomes (DoHuRu/POPC and DoHuRu/DOTAP) under the 
same in vitro experimental conditions described above and were then morphologically 
examined by a phase-contrast microscope (Labovert microscope, Leizt) for autophagic 
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vacuoles and apoptotic markers. Microphotographs at a 200 × total magnification (20 × 
objective and 10 × eyepiece) were taken with a standard VCR camera (Nikon).  
 
 
 
4.5 Fluorescence microscopy and fluorescent probes 
To evaluate the cellular uptake of the liposome, rhodamine B lipid derivative, 1,2- dioleoyl-
sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium salt 
(λex 560 - λem 583 nm) (Figure 19), was used as a fluorescent probe by adding 2% mol 
during the synthesis of DoHuRu/DOTAP liposome. Sterile coverslips were placed in twenty-
four-well plates. MCF-7 cells were seeded at a concentration of 5×104/ml in the same 
twenty-four-well plates. Following a growth period of 24 h at 37°C in RPMI 1640 medium 
containing 10% FBS, the medium was replaced with serum-free RPMI 1640 medium, which 
was followed by the addition of fluorescent liposomes at final concentration 100 μM or free 
PBS saline solution to each well. The cells were incubated for additional times (30 min, 1, 3 
and 6 h) with liposomes and washed with PBS three times to remove unassociated liposomes. 
The cells were then fixed at room temperature in 4% paraformaldehyde for 20 min. After 
washing with PBS three times, the cells were treated with diaminophenylindole (DAPI) 
(Sigma) to stain the cell nuclei. The coverslip from each well was mounted onto a glass 
microslide with 80% fluorescence-free glycerol mounting medium. Finally, the interaction 
of liposomes with MCF-7 cells and the cellular uptake was monitored using a fluorescent 
microscope (Leica Microsystems GmbH, Wetzlar, Germany) to visualize DAPI (345/661 
nm) and fluorescent liposomes (557/571 nm). Images were taken using an AxioCam HRc 
video-camera (Zeiss) connected to an Axioplan fluorescence microscope (Zeiss) using the 
AxioVision 3.1 software. 
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Furthermore, a fluorescently labeled nucleolipid has been designed using HoThyRu as the 
model compound. The dansyl group (λex 370 - λem 450 - 550 nm) has been here selected to 
provide the fluorescent tag because it offers several advantages, for example, high chemical 
stability, limited steric hindrance compared to other commonly used fluorescent dyes, and 
simple installation protocols. In addition, dansyl derivatives are very sensitive to the solvent 
polarity conditions, thus providing relevant information on the local environment in which 
they are found. The dansyl-labeled nucleolipid Ru(III) complex (here indicated as 
HoThyDansRu) and depicted in Figure 19 thus contains the following moieties: 
• one pyridine-methyl arm at the N-3 position, as the privileged 
ligand for the ruthenium complexation; 
• a dansyl group attached via a sulfate bridge at the 2′position; 
• one oleic acid residue at the 3′ position; 
• one hexa(ethylene glycol) chain, capped with a benzyl group, in 5′ position. 
 
 
 
Figure 19. Molecular structure of a) Rhodamine-based fluorescent probe and b) HoThyDansRu (Mangiapia et 
al., 2013). 
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4.6 Immunostaining and confocal microscopy 
For a detailed investigation of the cellular mechanism of action of the synthesized Ru(III) 
complexes, aiming at a deeper comprehension of their cell internalization process and 
metabolic fate, the fluorescent dansyl- labeled nucleolipidic complex HoThyDansRu (above 
described) has been used. Hence, human MCF-7 breast adenocarcinoma cells were exposed 
or not to 100 µM of the cationic dansylated HoThyDansRu/DOTAP nanoaggregate for 30 
min, 1, 2, 3, and 4 hours, in the same experimental condition described for bioscreen in vitro. 
After treatments, cells were fixed for 20 minutes with a 3% (w/v) paraformaldehyde (PFA) 
solution and permeabilized for 10 minutes with 0.1% (w/v) Triton X-100 in phosphate-
buffered saline (PBS) at room temperature. To prevent nonspecific interactions of 
antibodies, cells were treated for 2 h in 5% bovine albumin serum (BSA) in PBS. 
Immunostaining was carried out by incubation with Alexa Fluor 647 Anti-Human CD324 
(E-Cadherin) Antibody (BIOLEGEND) (Shamran et al., 2017); DAPI/Moviol Pro Long 
Diamond Antifade Mountant with Dapi (Invitrogen) was used as nuclear stain. The slides 
were mounted on microscope slides by Mowiol. The analyses were performed with a Zeiss 
LSM 510 microscope equipped with a plan-apochromat objective X 63 (NA 1.4) in oil 
immersion.  
 
 
 
4.7 Subcellular fractionation and ICP-MS analysis for ruthenium intracellular 
localization 
Breast cancer cells, such as MCF-7 and MDA-MB-231 cells, were grown on standard plastic 
100 mm culture dishes by plating 8 × 105 cells. After 24 h of growth, the cells were incubated 
with IC50 doses of the “naked” AziRu and DoHuRu/DOTAP liposome for 48 h under the 
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same experimental conditions described for bioscreens. At the end of the treatment, the 
culture medium was collected and the cells were enzymatically harvested by trypsin, then 
centrifuged at RT for 3 min at 1300 × g. The cell pellets obtained were, then, resuspended 
in 500 μl of a solution I (10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM MgCl2, 0.1 mM 
EDTA, 0.1 mM DTT, Protease Inhibitor Cocktail) and centrifuged at 2000 × g for 10 min at 
4°C. The supernatant, representing the cytosolic f raction, was separated from the pellets 
which instead contained the nuclear and mitochondrial fraction. Furthermore, the pellets 
were washed 3 times with the solution I and 200 μl of lysis buffer (10mM HEPES, 3 mM 
MgCl2, 40 mM KCl, 5% glycerol, 1 mM DTT, 0.2% NP40) was added and incubated for 30 
min in ice. After centrifugation at 4°C for 30 min at 1300 ×g, the pellets containing the 
nuclear fraction were obtained. 
Furthermore, to obtain the purified DNA fraction, the pellets were suspended in DNA lysis 
buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 100 mM NaCl, 1% SDS, 0.5 mg/mL 
Proteinase K) and incubated at 50 °C for 1 h. After incubation, 10 mg/ml RNase was added 
to the lysates and incubated for 1 h at 50°C. DNA was precipitated with NaOAc pH 5.2 and 
ice cold 100% EtOH and centrifuged at 14000 × g for 10 min. Pellets were dissolved in TE 
buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Aliquots of culture medium, cellular pellet, 
cytosolic fraction, nuclear fraction and DNA sample were analyzed by inductively coupled 
plasma-mass spectrometry (ICP-MS) to determine the ruthenium amounts.  
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Figure 20. Schematic representation of subcellular fractionation coupled to ICP-MSS spectrometry.  
 
 
 
4.8 DNA fragmentation assay 
MCF-7 and MDA-MB-231 cells were grown on standard plastic 60 mm culture dishes by 
plating 5 × 105 cells. After 24 h of growth the cells were treated for 48 h with IC50 doses of 
DoHuRu/ POPC and DoHuRu/DOTAP liposomes under the same experimental conditions 
described for bioscreens, as well as with IC50 doses of cisplatin (cDDP) - a positive control 
for in vitro apoptosis (Okamura et al., 2004). The DNA fragmentation assay was carried out 
as previously reported (Vitiello et al., 2015). After treatments, cells were collected and the 
pellets were suspended in lysis buffer (50 mM Tris-HCl, pH 8.0, 5 mM EDTA, 100 mM 
NaCl, 1% SDS, 0.5 mg/mL Proteinase K) and incubated at 50°C. After 1 h incubation, 10 
mg/ml RNase was added to the lysates and incubated for 1 h at 50 °C. DNA was precipitated 
with NaOAc pH 5.2 and ice cold 100% EtOH and centrifuged at 14000 × g for 10 min. 
Pellets were dissolved in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). A 20 μl aliquot 
of each DNA sample was analyzed on a 1.5% agarose gel stained with ethidium bromide 
and visualized under UV light. 
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4.9 FACS analysis 
Annexin V-FITC (fluorescein isothiocyanate) was used in conjunction with a vital dye, 
propidium iodide (PI), to differentiate apoptotic (Annexin V-FITC positive, PI negative) 
from necrotic (Annexin V-FITC positive, propidium iodide positive) cells (Misso et al., 
2013). Briefly, cells were incubated with Annexin V–FITC (MedSystems Diagnostics, 
Vienna, Austria) and propidium iodide (Sigma, St. Louis, MO, USA) in a binding buffer (10 
mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM CaCl2) for 10 min 
at room temperature, washed and resuspended in the same buffer. Analysis of apoptotic cells 
was performed by flow cytometry (FACScan, Becton 4 Dickinson) (Esposito et al., 2009). 
For each sample, 2 × 104 events were acquired. The study was carried out by triplicate 
determination on at least three separate experiments (Figure 21). 
 
 
 
Figure 21. Double method of PI and Annexin V detection of apoptosis by FACS analysis 
(www.lifesci.dundee.ac.uk). 
 
 
 
4.10 Labeling of autophagic vacuoles with monodansylcadaverine (MDC) 
To quantify the induction of the autophagic process, MCF-7 and MDA-MB-231 cells, 
treated with IC50 concentrations of the DoHuRu/POPC and DoHuRu/DOTAP formulations, 
were stained with the autofluorescent agent monodansylcadaverine (MDC), a selective 
73 
 
marker for autophagic vacuoles (AVOs), especially for autolysosomes (Grimaldi et al., 
2015). Treated cells were incubated with 50 μM MDC in PBS at 37°C for 15 min. After 
incubation, cells were washed twice with PBS, and immediately analyzed by flow cytometry 
with a FACScalibur flow cytometer (Becton Dickinson). The fluorescent emissions were 
collected through a 530 nm band pass filter (FL1 channel). At least 104 events were acquired 
in log mode. For the quantitative evaluation of MDC, CellQuest software (Becton 
Dickinson) was used to calculate mean fluorescence intensities (MFIs) (Figure 22). The 
MFIs were calculated by the formula (MFI treated/MFI control), where MFI treated is the 
fluorescence intensity of cells treated with the various compounds and MFI control is the 
fluorescence intensity of untreated and unstained cells. 
 
 
 
 
Figure 22. Schematic representation of the autophagic phases (www.frontiersin.org). 
 
 
 
4.11 Preparation of cellular extracts 
MCF-7 and MDA-MB-231 cells were cultured in standard plastic 60 mm culture dishes by 
plating 5 × 105 cells. Behind reaching the subconfluence, cells were incubated for 48 and 72 
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h with IC50 concentrations of the ruthenium-containing liposomes (DoHuRu/POPC and 
DoHuRu/DOTAP) under the same experimental conditions described above. After 
treatments, cells were washed and collected by scraping with PBS containing 1 mM EDTA 
and low-speed centrifugation. Cell pellets were then lysed at 4°C for 30 min in a buffer 
containing 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 5% (v/v) glycerol, 10 
mM NP-40 and protease inhibitor tablets (Roche) (Miniaci et al., 2016). The supernatant 
fraction was obtained by centrifugation at 15,000 × g for 10 min at 4°C and then stored at 
−80°C. Protein concentration was determined by the Bio-Rad protein assay (Bio-Rad, Milan, 
Italy). 
 
 
 
4.12 Western blot analysis 
For Western blot analysis, samples containing 30–50 μg of proteins were loaded on 10% 
SDS–PAGE and transferred to nitrocellulose membranes (Fiorito et al., 2013; Marra et al., 
2013). After blocking at room temperature in milk buffer [1 × PBS, 5–10% (w/v) non-fat 
dry milk, 0.2% (v/v) Tween-20], the membranes were incubated at 4°C overnight with: 
1:500 rabbit polyclonal antibody to human caspase-8 (Santa Cruz Biotechnology, Santa 
Cruz, CA); 1:500 mouse monoclonal antibody to human caspase-9 (Santa Cruz 
Biotechnology); 1:500 rabbit polyclonal antibody to human caspase-3 (Santa Cruz 
Biotechnology); 1:500 rabbit polyclonal antibody to human Bcl-2 (26 kDa) (Santa Cruz 
Biotechnology); 1:250 rabbit polyclonal antibody to human Bax (Santa Cruz Biotechnology, 
Santa Cruz); 1:1000 rabbit polyclonal antibody to human LC3B (Novus Biologicals); 1:100 
mouse monoclonal antibody to human BECN1(E-8) (Santa Cruz Biotechnology, Santa 
Cruz). Subsequently, the membranes were incubated with peroxidase-conjugated goat anti-
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rabbit IgG, or with peroxidase-conjugated goat anti-mouse IgG+IgM (all the secondary 
antibodies were purchased from Jackson ImmunoResearch Laboratories). The resulting 
immunocomplexes were visualized by the ECL chemoluminescence method (ECL, 
Amersham Biosciences Little Chalfont, Buckinghamshire, UK) and analyzed byan imaging 
system (ImageQuantTM400, GE Healthcare Life Sciences) (Russo et al., 2016). 
Densitometric analysis was conducted using the GS-800 imaging densitometer (Bio-Rad). 
Normalization of results was ensured by incubating the nitrocellulose membranes in parallel 
with the tubulin antibody. 
 
 
 
4.13 Analysis of CD4 T helper polarization in draining lymph nodes 
CD4+ T helper (TH) cells play a central role in the adaptive immune system. Indeed, 
according to the type of pathogens (extracellular-, intracellular pathogens), CD4+ Th cells 
will polarize either into Th1, Th2, Th9 or Th17. Thus CD4+ T cells secreting Th1 cytokines 
help macrophages and cytotoxic CD8 T cells to kill cancer or infected cells. Th2 cells secrete 
cytokine necessary for B cell differentiation into plasmocytes secreting antibodies. This type 
of adaptive immunity is necessary to eliminate extracellular pathogens. Finally, Th17 cells 
are mainly observed at the epithelial barriers where they help B and epithelial cells to block 
entrance of pathogens. Another type of CD4 T cells, named T regulators (Treg) are important 
in the tolerance. They secrete cytokine leading to the inhibition of immune cells. In order to 
study the polarization of CD4 helper T cells and the balance T effector/Treg, we choose to 
study gene expression of specific transcription factors or cytokines. The selected genes are 
represented in the Table 5.  
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Table 5. Main transcription factors and cytokines produced by the different populations of CD4 T cells. In 
bold appear the genes of which I analyzed expression. 
 
 
 
4.14 FACS and cell sorting 
Before analyzing the expression of these different genes, we need to purify CD4 T cells in 
the draining lymph nodes. To do that, the total cell population is stained with -CD4 and -
CD8 antibodies coupled to fluorochromes and isolated thanks to the FACS (Fluorescence-
activated Cell Sorting) (Figure 23). After isolation the CD4 T cells are lyzed and the total 
RNA are isolated according to the manufacturer’s instruction (Qiagen).  
 
 
 
Figure 23. Protocol of CD4 T cell isolation and RNA extraction. Cells obtained from the draining lymph node 
were stained with specific antibodies α-CD16-32, α -CD4-BV421, α -CD8 α -AF700, during 30 min at 4°C. 
One experiment is representative of 7. The CD4 were then isolated thanks to the FACS technology (ARIA) 
and the total RNA was extracted and analyzed. 
 
 
 
CD4 populations Transcription factors cytokines 
Th1 Tbet/Eomes IFN- 
Th2 GATA-3 IL-4 ; IL-10 
Th17 RORt IL-17 ; IL-22 
Treg FoxP3 TGF-; IL-10 
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4.15 RT-qPCR 
RT-qPCR can be performed in a one-step or a two-step assay. One-step assays combine 
reverse transcription and PCR in a single tube and buffer. In two-step assays (which we 
used), the reverse transcription and PCR steps are performed in separate tubes, with different 
optimized buffers, reaction conditions, and priming strategies. 
By using this method, gene expression profiles of tumour-infiltrating immune cells have 
been analyzed. In particular, IFN-ɣ (Fw: GGATGCATTCATGAGTATTGC; Rv: 
CCTTTTCCGCTTCCTGAGG) , Tbet (Fw: GATCATCACTAAGCAAGGACGGC; Rv: 
AGACCACATCCACAAACATCCTG), IL-4 (Fw: TCGGCATTTTGAACGAGGTC; Rv: 
GAAAAGCCCGAAAGAGTCTC), FoxP3 (Fw: CACCCAGGAAAGACAGCAACC; Rv: 
GCAAGAGCTCTTGTCCATTGA) were analyzed. The housekeeping genes used are: 
GADPH (Fw: TGCGACTTCAACAGCAACTC; Rv: ATGTAGGCCATGAGGTCCAC); 
Rpl13 (Fw: ACAGCCACTCTGGAGGAGAA; Rv: GAGTCCGTTGGTCTTGAGGA); 
PPIA (Fw: TGGAGAGAAAGGATTTGGCTA; Rv: AAAACTGGGAACCGTTTGTG); 
b2m (Fw: ACTGATACATACGCCTGCAGAGTT; Rv; 
TCACATGTCTCGATCCCAGTAGA) and SDHA (Fw: 
ACACAGACCTGGTGGAGACC; Rv: GGATGGGCTTGGAGTAATCA). 
 
 
4.16 Statistical analysis 
All data were presented as mean values ± SEM. The statistical analysis was performed using 
Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for multiple 
comparisons was performed followed by Bonferroni’s test. 
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5.1 In vitro bioscreens for anticancer activity 
The antiproliferative properties of the liposomes containing the Ru(III)-nucleolipids were 
screened on human breast cancer models by means of selected mammary malignant cells 
endowed with different phenotypic and/or genotypic features and different replicative and/or 
invasive potential (MCF-7, CG-5, MDA-MB-231, MDA-MB-468 and MDA-MB-436 cell 
lines). The concentration-effect curves (Figure 24) - here reported in terms of a “cell survival 
index” (CSI) which combines the measurements of cell number and viability - show a typical 
concentration-dependent sigmoid trend yielding IC50 values in the low micromolar range. In 
particular, CSI is an adimensional value calculated by the arithmetic mean between the 
percentage values emerging from the MTT assay (a functional assay to evaluate cell 
viability) and the automated cell count (to determine the live/dead cells ratio). The 
simultaneous evaluation of cell survival by means of both a functional parameter and the 
actual number of live/dead cells allows for a more accurate information about cellular 
response to treatments during preclinical in vitro testing. According to the IC50 values (Table 
6), the ToThyRu/DOTAP and DoHuRu/DOTAP formulations are the most effective in 
reducing the proliferation of all the used cell lines. This result, consistent with our previous 
reports, is likely associated to the positive charge of DOTAP formulations which can 
promote the interaction with the plasma membranes allowing a faster and quantitative drug 
cellular uptake (Mangiapia et al., 2013). Moreover, in relation to their effectiveness in vitro, 
there are no significant differences between the ToThyRu and DoHuRu nucleolipidic Ru(III) 
complexes used in our liposomial formulations, consistently with the rationale that the 
ruthenium center is the bioactive species, and the nucleolipids are simply carrier molecules 
(Riccardi et al., 2017). IC50 data normalization in favour of the actual ruthenium content 
enclosed in ToThyRu/DOTAP and DoHuRu/DOTAP liposomes (15% mol/mol), leads up to 
values of IC50 of about 3–4 μM in CG-5 cells and of about 10 μM in MCF-7 cells, suggestive 
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of a marked antiproliferative bioactivity in vitro. Overall, the calculated ruthenium IC50 
values for DOTAP liposomes are in the low micromolar range (≤ 20 μM), similar or lower 
than those measured for cisplatin used in the same experimental conditions as a reference 
drug. All the breast cancer cells used in this screening are therefore sensitive to the action of 
metal-based drugs. The ruthenium IC50 values relative to cell growth inhibition in the 
presence of ToThyRu/POPC and DoHuRu/POPC formulations are also relevant, reaching 
values below 20 μM as in the case of MDA-MB-468, MCF-7 and CG-5 cancer cells. 
Looking further at IC50 values, the “naked” low molecular weight Ru(III) complex AziRu 
exhibits a milder antiproliferative activity on the same breast cancer cells, showing IC50 
values constantly greater than 250 μM. These values are generally in agreement with those 
reported in the literature for the antimetastatic NAMI-A (Groessl et al., 2007), and once more 
highlight the critical importance of the delivery strategy to ensure the drug stability in the 
extra-cellular environment, a quantitative transport across the membranes and the 
bioavailability at the biological targets. Noteworthy, the bioactivity potentiating factors 
calculated as the ratio of IC50 values of the Ru(III)-containing liposomes with respect to the 
IC50 of AziRu, reach values of more than 20 in terms of antiproliferative ability (Vitiello et 
al., 2015). 
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Figure 24. Cell survival index, evaluated by the MTT assay and monitoring of live/dead cell ratio for MCF-7, 
MDA-MB-231, MDA-MB-436, MDA-MB-468, and CG-5 cell lines following 48 h of incubation with the 
indicated concentration (the range 1 → 1000 μM has been explored, the one 1 → 250 μM is shown) of AziRu, 
and of the ruthenium-containing (15% mol/ mol) POPC formulations (ToThyRu/POPC and DoHuRu/POPC) 
and DOTAP formulations (ToThyRu/DOTAP and DoHuRu/DOTAP), as indicated in the legend. Data are 
expressed as percentage of untreated control cells and are reported as mean of five independent experiments ± 
SEM (n = 30). 
 
 
 
 
 
Table 6. IC50 values (μM) relative to the specified POPC and DOTAP ruthenium-containing liposomes, and 
to cisplatin (cDDP), used as cytotoxic reference drug, and to the naked Azi-Ru complex in the listed breast 
cancer cell lines following 48 h of incubation. The ruthenium IC50 values corresponding to the effective metal 
concentration (15% mol/mol) carried by each nanoaggregate are reported as mean values ± SEM (n = 30). (NA 
= not assessed). 
 
 
 
 
 
Cell lines
Total 
liposome
Ru
Total 
liposome
Ru
Total 
liposome
Ru
Total 
liposome
Ru AziRu c DDP
MCF-7 185 ± 0.1 27.8 ± 0.1 126 ± 0.1 18.9 ± 0.1 74.6 ± 0.1 10.1 ± 0.1 67.3 ± 0.2 10.3 ± 0.2 >250 17 ± 1
MDA-MB-231 239 ± 3 35.8 ± 3 98 ± 1 14.7 ± 1 79.5 ± 0.2 10.8 ± 0.2 81 ± 0.3 12.1 ± 0.3 >250 19 ± 1.5
MDA-MB-436 >250 >37.5 245 ± 1 36.7 ± 1 110 ± 0.2 15.0 ± 0.2 130.9 ± 0.2 20.0 ± 0.2 >250 NA
MDA-MB-468 111.1 ± 0.1 15.7 ± 0.1 136 ± 0.8 20.4 ± 0.8 107.8 ± 0.1 14.7 ± 0.1 95 ± 0.1 14.2 ± 0.1 >250 24 ± 1
CG-5 138 ± 0.2 19.4 ± 0.2 204 ± 0.8 30.6 ± 0.8 30.1 ± 0.2 4.1 ± 0.2 21.5 ± 0.2 3.3 ± 0.2 >250 NA
IC50(μM±SEM)
ToThyRu/POPC DoHuRu/POPC ToThyRu/DOTAP DoHuRu/DOTAP
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5.2 Cellular morphological changes 
Monitoring the cellular morphological changes over time can provide an additional support 
to the antiproliferative effects produced by ruthenium-based nanoaggregates. Throughout 
the in vitro trials, imaging end-points were collected by light microscopy from cells to assess 
cellular morphological changes induced by drug administration. Microphotographs in Figure 
25a of MCF-7 and MDA-MB-231 breast adenocarcinoma cells, nowadays among the most 
reliable in vitro models of breast cancer, in the presence of DoHuRu/POPC and 
DoHuRu/DOTAP (at their IC50 concentrations for 48 and 72 h) are suggestive of the 
characteristic cell shrinkage as well as loss of cell-cell contact that accompanies apoptosis 
occurrence. Moreover, after in vitro treatments cells were morphologically examined at a 
higher magnification by a phase-contrast microscope for autophagic vacuoles formation. As 
shown in Figure 25b, in addition to apoptotic hallmarks, autophagic vacuoles clearly appear 
when MCF-7 cells were treated with the DoHuRu/DOTAP liposomes for 48 h at IC50 
concentration, providing a morphological support of autophagy activation. These 
observations were further confirmed by FACS analysis, discussed below. Thus, the AziRu 
in vitro treatment by the DoHuRu/POPC liposome seems to trigger exclusively apoptosis, 
whereas the one with the cationic DoHuRu/DOTAP seems to simultaneously activate 
apoptosis and autophagy. 
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Figure 25. Cytomorphological alterations on cell monolayers (a) Representative microphotographs at a 200 × 
magnification (20 × objective and a 10 × eyepiece) by phase-contrast light microscopy of MCF-7 (left panels) 
and MDA-MB-231 (right panels) breast cancer cells treated for 48 and 72 h with ruthenium IC50 micromolar 
concentrations of DoHuRu/POPC (18.9 and 14.7 μ M, respectively) and DoHuRu/DOTAP liposomes (10.3 
and 12.1 μM, respectively), showing the cellular morphological changes and the cytotoxic effects on cell 
monolayers. The shown images are representative of three independent experiments. (b) Representative 
microphotographs of untreated (left panel) and 48 h DoHuRu/DOTAP treated (right panel) MCF-7 cells by 
phase-contrast light microscopy at a 600 × magnification (30 × objective and a 20 × eyepiece). 
DoHuRu/DOTAP (at IC50 concentration) induces the formation of autophagic vacuoles detectable in cell 
cytoplasm. Inset: higher magnifications of MCF-7 cells before and after treatment. 
 
 
 
5.3 Pro-apoptotic effects in breast cancer cells 
Changes both in the cell morphology and in the monolayers appearance suggest that 
liposomes containing the nucleolipidic Ru(III)-complexes might have chemotherapeutic 
effects in human breast cancer initiating cells towards specific cell death pathways. The 
evaluation of apoptosis induction via FACS analysis has revealed that both DoHuRu/POPC 
and DoHuRu/DOTAP formulations are able to induce remarkable pro-apoptotic effects on 
MCF-7 cells and MDA-MB-231. In fact, as depicted in Figure 26a,c with reference to MCF-
7 cells, the 46% of total cell population is in advanced stage of apoptosis following 48 h of 
exposure to IC50 concentrations of DoHuRu/DOTAP; further 24 h of treatment results in the 
84 
 
82% of cell population in late apoptosis phase. Milder pro-apoptotic effects, but nonetheless 
of significance, are detected in the case of DoHuRu/POPC treatment, leading after 48 h to 
about 36% of total MCF-7 cell population in early apoptosis and to a 37% in late apoptosis 
after 72 h. As a further validation of these data, no significant signals of apoptosis 
perturbation, such as an increased necrosis, were detectable by FACS analysis. A similar 
distribution of cell population among the different apoptotic stages has been observed by 
investigating the effects of liposomes containing nucleolipidic Ru(III)-complexes on MDA-
MB-231 cells (Figure 26b,d), confirming the increased in vitro efficacy - especially as a 
trend over time - of the cationic nanoaggregates (i.e., the DoHuRu/DOTAP ones) with 
respect to the zwitterionic POPC ones. This scenario is fully consistent with our previous 
studies (Mangiapia et al., 2013;Vitiello et al., 2015). As a result of different cellular uptake 
kinetics, ruthenium-containing cationic liposomes (DoHuRu/DOTAP) induce faster 
biological effects by way of cellular apoptosis activation than those dependent by the neutral 
liposomes (DoHuRu/POPC). 
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Figure 26. Induction of apoptosis in MCF-7 and MDA-MB-231 breast cancer cells. Apoptosis was evaluated 
by FACS analysis, after cell labeling with propidium iodide (PI) and FITC-Annexin V. MCF-7 (a) and MDA-
MB-231 (b) cells were both unlabeled and untreated (CTR−), labeled and not treated (CTR + ), treated with 
DoHuRu/POPC or with DoHuRu/DOTAP for 48 and 72 h using IC50 concentrations, as indicated. The lower 
left quadrants of each panels show the viable cells, which exclude PI and are negative for FITC-Annexin V 
binding. The upper left quadrants contain the non-viable, necrotic cells, negative for FITC-Annexin V binding 
and positive for PI uptake. The lower right quadrants represent the cells in early apoptosis, that are FITC 
Annexin V positive and PI negative. The upper right quadrants represent the cells in late apoptosis, positive 
for both FITC-Annexin V binding and for PI uptake. The experiments were performed at least three times with 
similar results. Quantitative analysis of viable, non-viable (necrotic), early and late apoptotic MCF-7 (c) and 
MDA-MB-231 (d) cells after 48 and 72 h of treatments are shown. Data are expressed as percentage of 
untreated control cells and are reported as mean of four independent experiments ± SEM (n = 24); ***p < 
0.001 vs. control (untreated cells). 
 
 
 
5.4 DNA fragmentation in MCF-7 and MDA-MB-231 breast cancer cells 
It is generally accepted that DNA damage and subsequent induction of apoptosis is the 
primary cytotoxic mode of action of cisplatin and other metal-based antiproliferative drugs. 
In addition to shrinkage and fragmentation of the cells and nuclei, the apoptotic process is 
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accompanied by degradation of the chromosomal DNA into nucleosomal units. Indeed, late 
events of apoptosis typically lead to DNA cleavage, resulting in a “ladder” formation 
detectable by agarose gel electrophoresis. To verify apoptosis induction in breast cancer cells 
in a direct manner, we analyzed DNA degradation on genomic DNA samples obtained from 
treated cells. As depicted in Figure 27, though with a non-canonical nuclear fragmentation 
pattern in MCF-7 due to inherent caspase-3 expression deficiency, the DNA damage 
markedly increased in cells exposed to both DoHuRu/POPC and DoHuRu/DOTAP for 48 h 
at IC50 doses. Moreover, the typical internucleosomal DNA laddering of cell undergoing 
apoptosis clearly appeared in MDA-MB-231 cells, with a fragmentation pattern similar to 
that induced by IC50 doses of cisplatin in vitro, herein used as positive control (Okamura et 
al., 2004). 
 
 
 
Figure 27. DNA fragmentation assay on MCF-7 and MDA-MB-231 cells treated or not (C) with IC50 
concentrations of DoHuRu/POPC (RuPOPC) and DoHuRu/DOTAP (RuDOTAP) for 48 h, and with IC50 doses 
(17 and 19 μM, respectively) of cisplatin (cDDP) as the positive control for DNA fragmentation. After 
incubation, the DNA was extracted and visualized on 1.5% agarose gel as detailed in the Methods section. The 
lane in the middle corresponds to the molecular weight markers. The agarose gel is representative of three 
independent experiments. 
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5.5 Apoptotic-related proteins in MCF-7 and MDA-MB-231 breast cancer cells 
Given that the expression profile of pro-apoptotic proteins is a central determinant for the 
death mode induced by ruthenium-based drugs, we analyzed the expression of proteins 
linked to the two main pathways that control mammalian apoptosis, i.e. the extrinsic (or 
death receptor) and intrinsic (or mitochondrial) apoptotic pathways. As determined by 
Western blot analysis reported in Figure 28a,c,e, protein extracts from MCF-7 exposed for 
48 and 72 h to IC50 concentrations of DoHuRu/POPC and DoHuRu/DOTAP showed a 
remarkable increase in caspase-9 activity compared with control, whereas in the same 
experimental conditions no caspase-8 activation was detectable. Indeed, the activation of 
pro-caspase-9 involves intrinsic proteolytic processing, resulting in the production of an 
active p35 subunit. Moreover, as clearly detectable by immunoblot, an additional cleavage 
occurred producing a large p37 subunit which is known to amplify the apoptotic response. 
On the other hand, full length pro-caspase-8 expression was not affected by in vitro 
treatments. Taken together, these results suggest a ruthenium-dependent activation of the 
apoptotic mitochondrial pathway, wherein Bax and Bid are key cell death factors increasing 
mitochondrial permeability and release of cytochrome c. Conversely, cell survival factor 
Bcl-2 inhibits actions of Bax and Bid on mitochondria (Zheng et al., 2016). In MCF-7 cells 
Bax was significantly increased and Bcl-2 decreased upon DoHuRu/POPC and 
DoHuRu/DOTAP treatment - a cellular response predisposing to apoptosis activation. These 
biological effects were time-dependent and more evident following in vitro treatment with 
the cationic DoHuRu/ DOTAP liposomes. In the same way, ruthenium treatment in MDA-
MB-231 breast cancer cells via DoHuRu/POPC and DoHuRu/ DOTAP in vitro 
administration at IC50 concentrations elicited caspase-9 activation after 48 h, and this anew 
was coupled to the simultaneous Bax and Bcl-2 up-regulation and down-regulation, 
respectively (Figure 28b,d,f). Furthermore, in this breast cancer cell line DoHuRu/DOTAP 
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seemed able to promote full length pro-caspase-8 cleavage, as evidenced by the formation 
of the active p10 and p18 fragments. In turn, activated initiator caspases further process other 
caspase members, including caspase-3 and caspase-7, to initiate a caspase cascade, which 
generally leads to complete the programmed cell death process. In fact, the immunoblotting 
analysis performed on MDA-MB-231 cells exposed to Ru(III)-containing liposomes further 
revealed a marked proteolytic cleavage of the inactive proenzyme to activate caspase-3. 
Hence, the evaluation of apoptosis regulatory proteins in breast cancer models for the in vitro 
preclinical evaluation of ruthenium biological effects suggests the invariable induction of 
the mitochondrial apoptotic cell death pathway, but also the cell-specific activation of the 
extrinsic death pathway particularly in the case of the cationic nanoaggregate. Interestingly, 
the treatment with either DoHuRu/POPC or DoHuRu/DOTAP alters the expression profile 
of Bax and Bcl-2 proteins with respect to basal amounts, radically changing the Bax/Bcl-2 
ratio. The Bax up-regulation and Bcl-2 down-regulation observed in concert following 
ruthenium action may predispose cells to apoptosis (Zheng et al., 2016). 
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Figure 28. Apoptotic regulatory proteins in MCF-7 and MDA-MB-231 cells. Western blot analysis showing 
the effects of IC50 concentrations of DoHuRu/POPC and DoHuRu/DOTAP following 48 and 72 h of 
incubations in MCF-7 (a) and MDA-MB-231 (b) cells on caspases-3, -8 and -9 expression and activation, and 
on Bax and Bcl-2 expression, to characterize the apoptotic response. Shown are blots representative of four 
independent experiments. After chemoluminescence, the bands resulting from MCF-7 (c, e) and MDA-MB-
231 (d, f) cell extracts were quantified by densitometric analysis and plotted in line (solid and dotted line for 
Bax and Bcl-2 proteins, respectively) and bar (caspases-3, -8 and -9) graphs as percentage of control in relation 
to the used ruthenium-containing nanoaggregate, as indicated. Shown are the average ± SEM values of four 
independent experiments. The anti-tubulin antibody was used to standardize the amounts of proteins in each 
lane. **p < 0.01 vs. control cells; ***p < 0.001 vs. control cells. 
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5.6 Autophagy activation in MCF-7 and MDA-MB-231 breast cancer cells 
In addition to apoptosis, cellular suicide can also be executed via non-apoptotic forms of 
programmed death such as autophagy. The simultaneous evaluation of apoptosis and 
autophagy by means of the herein used methods is not mutually exclusive, i.e. it is possible 
to ascertain the degree of autophagy independently from that of apoptosis. Thus, to 
investigate whether DoHuRu/POPC and DoHuRu/DOTAP can also induce autophagy in 
MCF-7 and MDA-MB-231 cells, we have examined the formation of autophagic vacuoles 
using monodansylcadaverine (MDC), a selective autofluorescent dye for autolysosomes 
detection. Autolysosomes occurrence, which results from lysosomes-autophagosomes 
fusion, exclusively characterizes late steps in the autophagic cell death process. In order to 
verify this circumstance, cells were exposed for 48 and 72 h to ruthenium IC50 concentrations 
enclosed within DoHuRu/POPC and DoHuRu/DOTAP nanoaggregates (18.9 and 10.3 μM, 
respectively for MCF-7, 14.7 and 12.1 μM, respectively for MDA-MB-231) and the 
quantitative evaluation of MDC staining by means of FACS analysis was performed (Figure 
29). As a result of MDC accumulation and consistently with phase contrast cell imaging, the 
cationic DoHuRu/DOTAP formulation induced an evident increase in the Mean 
Fluorescence Intensity (MFI), in particular 4.3 and 5.8-fold higher at 48 and 72 h for MCF-
7, and 3.9 and 5.3-fold higher for MDA-MB-231 than untreated control cells. These results 
indicate an increased formation of the MDC-labeled vacuoles after ruthenium treatment via 
DoHuRu/DOTAP cationic liposomes and suggest the activation of autophagy in presence of 
apoptosis. Conversely, by using the zwitterionic DoHuRu/POPC liposomes, no significant 
autolysosomes formation was detected, at least up to 72 h. 
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Figure 29. Autophagy activation in MCF-7 and MDA-MD-231 breast cancer cells.  
Quantitative flow cytometric analysis of autophagosomes formation (MDC incorporation) in MCF-7 (a) and 
MDA-MB-231 (b) breast cancer cells, unlabeled and untreated (CTR−), labeled and untreated (CTR+ ), treated 
with IC50 concentrations of DoHuRu/POPC or with DoHuRu/DOTAP for 48 and 72 h, as indicated. The main 
fluorescence intensities (MFIs) were calculated, as described in ‘Materials and Methods’. In the corresponding 
bar graphs, values are expressed as percentage of control cells and are reported as mean of four independent 
experiments ± SEM (n = 24); ***p < 0.001 vs. control (untreated cells). 
 
 
 
5.7 Evaluation of the expression of the main autophagy-related proteins 
Autophagy is bulk degradation of cytoplasmic components during which double-membrane 
vesicles, called autophagosomes, carry unwanted cell components to the lysosomes within 
an inner autophagic membrane. They then fuse liberating the autophagic body and its 
contents into the lumen of the vacuole for degradation. This is a complex process involving 
at least 16 proteins (Divac et al., 2017). However, LC3 is the only one known to form a 
stable association with the membrane of autophagosomes. It is known to exist in two forms: 
LC3-I, which is found in the cytoplasm and LC3-II, which is membrane-bound and is 
converted from LC3-I, to initiate formation and lengthening of the autophagosome (Ngabire 
and Kim, 2017). In this frame, detection of LC3 expression by immunoblot analysis is a 
useful biomarker to detect possible autophagy activation.  
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As can be evidently observed in Figure 30, protein samples from MCF-7 and MDA-MB-231 
show evidence of a significant increase in both forms of LC3 protein following exposure in 
vitro to DoHuRu/DOTAP cationic Ru(III)-containing liposomes. Antibody for LC3 
detection recognizes both the forms: LC3-II differs from LC3-I only in the fact it is 
covalently modified with lipid extensions and has undergone removal of a short amino acid 
sequence (Romao et al., 2014). This scenario is consistent with the previous reported 
detection of autophagic vacuoles in the same experimental conditions, as well as of 
autolysosomes occurrence in late steps of autophagic cell death process. Hence, allowing for 
the role of LC3 within the autophagic pathway and in the light of all the obtained data, 
DoHuRu/DOTAP is able to induce autophagy activation in addition to apoptosis, the main 
pathways of programmed cell death inhibiting the uncontrolled proliferation of cancer cells 
in vitro. On the other hand but still in accordance with the results shown above, the treatment 
with the zwitterionic DoHuRu/POPC formulation results in a non-significant increase in 
LC3 protein, thus suggestive of no autophagy activation. 
These data were further substantiated by the study of the expression of the regulatory protein 
Beclin 1 throughout preclinical in vitro evaluations. Beclin 1 - a Bcl2 interacting protein - is 
the first identified mammalian gene to mediate autophagy and also has tumour suppressor 
and antiviral function (Ngabire and Kim, 2017). As already mentioned, autophagy is 
important for differentiation, survival during nutrient deprivation, and normal growth 
control, and is often defective in tumour cells. Indeed, expression of the Beclin 1 protein is 
frequently decreased in malignant breast epithelial cells (Packer et al., 2015). Based upon 
these observations, it is speculated that Beclin 1 may work through induction of autophagy 
to negatively regulate tumorigenesis and to control viral infections. Indeed, the autophagy-
promoting activity of Beclin 1 in MCF-7 cells is associated with inhibition of cellular 
proliferation (Gong et al., 2013). Whilst not disposing of the healthy counterpart of MCF-7 
93 
 
cells as appropriate control to actually detect Beclin 1 down-regulation in cancer cell models, 
immunoblot experiments here show there are not neither significant changes following 
exposure to both neutral and cationic nucleolipidic Ru(III)-containing liposomes, nor further 
decrease in protein content with respect to untreated cells. This invariable basal amount of 
Beclin 1 we have detected in treated or not MCF-7 and MDA-MB-231 adenocarcinoma cells 
would be essential to enable the possible activation and execution of autophagic pathways 
following the administration of ruthenium-based drugs in vitro, as demonstrated by previous 
experiments. Certainly, some recent experimental evidences have shown a lack of autophagy 
pathways following total Beclin 1 depletion induced by different conditions.  
 
 
 
Figure 30. LC3 protein expression in MCF-7 and MDA-MB-231 cells. Western blot analysis showing the 
effects of IC50 concentrations of DoHuRu/DOTAP following 48 and 72 h of incubations in MCF-7 (a) and 
MDA-MB-231 (b) cells on LC3-I and LC3-II, to characterize the autophagic response. Shown are blots 
representative of four independent experiments. The anti-β-actin antibody was used to standardize the amounts 
of proteins in each lane.  
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Figure 31. Beclin 1 protein expression in MCF-7 and MDA-MB-231 cells. Western blot analysis showing the 
effects of IC50 concentrations of DoHuRu/DOTAP following 48 and 72 h of incubations in MCF-7 (a) and 
MDA-MB-231 (b) cells on Beclin1, to characterize the autophagic response. Shown are blots representative 
of four independent experiments. The anti-β-actin antibody was used to standardize the amounts of proteins in 
each lane.  
 
 
 
5.8 Sub-cellular compartmentalization and localization of Ru complexes 
The internalization and accumulation of metal-based drugs into cancer cells is crucial for the 
therapeutic effect against tumours (McQuitty, 2014). For this reason, as already described in 
the introduction, we have previously investigated nucleolipidic Ru-containing liposomes 
interactions with cell membranes, along with the cell internalization processes (Mangiapia 
et al., 2012). To this aim, standardized protocol based on a rhodamine B fluorescent probe 
loaded into POPC and DOTAP liposomes has been used to evaluate their uptake in human 
carcinoma cells. Furthermore, additional in vitro fluorescence experiments have been 
performed by dansyl-labeled ruthenium complex loaded into nucleolipidic liposomes in 
order to assess the fate of the active ruthenium complex once inside target cancer cells. In 
this way we have demonstrated that nucleolipidic nanoaggregates rapidly interact with 
biological membranes allowing a massive cellular uptake, even after short incubation times 
such as 30 min and 1 h, in a process of cell internalization probably occurring by nonspecific 
patterns via membrane fusion and/or endocytosis. Therefore, once the ability of our 
nanovectors to transport the active ruthenium to cancer cells has been established, to give an 
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insight into the action mechanism of the AziRu complex so as to suppose possible 
interactions with specific biomolecular targets, new and more targeted experiments have 
been carried out to determine the accurate subcellular location of the active ruthenium. In 
particular, using ad hoc designed fluorescent formulations and confocal microscopy 
approaches, coupled to subcellular fractionation and inductively coupled plasma-mass 
spectrometry (ICP-MS), we have now further confirmed that Ru-nanovectors have a high 
propensity to cross cell membranes, and to massively accumulate within both cytoplasm and 
nuclear compartment, thus allowing ruthenium to interact with mitochondrial and nuclear 
molecular targets. 
As far as confocal microscopy is concerned, aiming at a deeper comprehension of their cell 
internalization process and metabolic fate, a fluorescently labeled nucleolipid has been 
designed using HoThyRu as the model compound, as detailed in the experimental section. 
The dansyl group has been here selected to provide the fluorescent tag because it offers 
several advantages, e.g. high chemical stability, limited steric hindrance compared to other 
commonly used fluorescent dyes, and simple installation protocols. In addition, dansyl 
derivatives are very sensitive to the solvent polarity conditions, thus providing relevant 
information on the local environment in which they are found (Giordano et al., 1985). The 
dansyl-labeled nucleolipid Ru(III) complex - here indicated as HoThyDansRu - has been co-
aggregated with DOTAP under the same conditions used for HoThyRu, ToThyRu, and 
DoHuRu (Mangiapia et al., 2013). In this way, the fate of the active ruthenium complex can 
be directly assessed, thereby examining its location after nanocarriers application to cells 
monolayers. Consistently with our previous results, fluorescently labeled 
HoThyDansRu/DOTAP localizes rapidly within MCF-7 cells, and microphotographs in 
Figure 32 clearly show a time course accumulation as the duration of incubations increased. 
The dansyl-dependent fluorescence occurs after very short contact times, and following 2 
96 
 
hours from the start of the treatment the fluorescent maximum diffusion is reached. 
Accordingly, the analysis of fluorescent emission also suggests that the complexes lodged 
in DOTAP liposomes enter the cytoplasm, spreading then to the whole cell including the 
perinuclear compartment; moreover, although attenuated by DAPI nuclear staining, dansyl-
dependent fluorescence emission is also detectable in the nuclei area. After 4 hours of 
contact, cytotoxic effects induced on MCF-7 by ruthenium-containing liposomes begin to 
be detectable, e.g. altered adherens-junctions to bind cells together, as it is evident by the 
appraisal of the red E-cadherine-associated fluorescence. Cadherins are a class of type-1 
transmembrane proteins which play important roles in cell adhesion, forming adherens 
junctions. They are dependent on calcium (Ca2+) ions to function, hence their name. Cell-
cell adhesion is mediated by extracellular cadherin domains, whereas the intracellular 
cytoplasmic tail associates with a large number of adaptor and signaling proteins, 
collectively referred to as the cadherin adhesome (Shamran et al., 2017). Overall, in addition 
to demonstrating an effective process of cellular uptake, the fluorescent patterns seem to 
suggest an intracellular liposome degradation coupled with the release of the 
pharmacologically active agent within the cytoplasm. This would explain the widespread 
dansyl-associated fluorescence and the concomitant generation of discrete dansyl-associated 
spots following cellular uptake and disaggregation of nanocarriers.  
All these data on AziRu intracellular and metabolic fate following nucleolipidic liposomes 
application to cells were further confirmed by subcellular fractionation protocols performed 
on MCF-7 adenocarcinoma cells, coupled with subsequent analysis by inductively coupled 
plasma-mass spectrometry (ICP-MS). As shown in bar graph in Figure 33 and in comparison 
to the naked Azi-Ru complex, ruthenium assessment and localization in breast cancer cells 
after treatments in vitro firstly prove that cellular uptake is considerably increased by suitable 
nanovehiculation: although sufficiently lipophilic, much of Azi-Ru remains in the culture 
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medium, whereas large amounts of ruthenium are found at cellular level after treatment with 
DoHuRu/DOTAP liposome. Moreover, ICP-MS analysis performed on the isolated 
subcellular fractions indicate that the liposomial ruthenium entering the cells is widely 
distributed amongst the intracellular compartments, but above all at the nuclear level, as 
evidenced by the high metal content bound to nuclear DNA. 
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Figure 32. Fluorescent microphotographs by confocal microscopy of cell monolayers showing the intracellular 
localization of dansylated-HoThyDansRu complex into human MCF-7 breast adenocarcinoma cells subsequent 
to nanocarriers application. MCF-7 were incubated with 100 μM of the intrinsically fluorescent 
HoThyDansRu/DOTAP liposome solution for 30 min, 1, 2, 3, and 4 h. DAPI is used as a nuclear stain (shown 
in blue); fluorescent immunostaining of E-cadherine is used to highlight cell membranes (shown in red); 
dansyl-dependent fluorescence in  HoThyDansRu/DOTAP liposomes is used to label the AziRu complex 
(shown in green). (a) In merged images of the time course experiment, the three fluorescent emissions are 
overlapped. The images shown are representative of three independent experiments. (b) Merged images and 
green channel imaging during the time course experiments to analyze the intracellular distribution of AziRu 
following 100 µM HoThyDansRu/DOTAP administration to MCF-7 for the indicated times. 
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Figure 33. Localization and ruthenium accumulation by Inductively Coupled Plasma-Mass Spectrometry 
(ICP-MS) analysis following AziRu and DoHuRu/DOTAP application to MCF-7 cells and subcellular 
fractionation protocols, as deeply described in the experimental section. As shown in bar graph, and in 
comparison to the naked AziRu complex, the ruthenium assessment and localization in breast cancer cells after 
treatments with the cationic DoHuRu/DOTAP liposome is investigated, making an allowance for culture 
medium and cellular pellets, and for the subcellular cytosolic and nuclear compartments, as well as for DNA 
fraction. 
 
 
 
5.9 Analysis of Th1 and Th2 related gene expression and EPO impact on Treg 
population 
The data obtained show that gene expression of IFN-ɣ and Tbet is higher in PBS mice 
compared to EPO one at D14 after 4T1 engraftment (Figure 34, left and middle panel). At 
D16 and D20, expression of these genes is low in PBS and EPO groups (data not shown). 
Thus, EPO decreases the differentiation of CD4 T cells into Th1 profile. Surprisingly, 
whereas it is well known that Th1/Th17 cytokines inhibit Th2 development and vice and 
versa, we observed that at days 16 and 20, the gene expression level of IL-4 is also reduced 
in EPO mice (Figure 34, right panel). This last result needs to be confirmed, as the number 
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of experiment is low. Moreover, the analysis of IL-10 and GATA-3 gene expression will 
increment these preliminary results on EPO’s effect on Th2 polarization.  
 
 
 
Figure 34. Analysis of Th1 and Th2 related gene expression. Gene expression of CD4 T cells from draining 
lymph node was analyzed on Light Cycler 480 (Roche) according to the manufacturer’s instructions. At d14 
n=4, D16 n=1, D20 n=2. Statistics: unpaired t test, *p<0.05, **p<0.01, ***<0.001. 
 
 
 
As Treg suppress immune response, we also analyze effect of EPO on this population. To 
do so, we studied their specific transcription factor FoxP3 by RT-qPCR and evaluated the 
Treg number in the dLN. There is neither difference in the expression of FoxP3 gene in the 
CD4 population (Figure 35, left panel), nor difference in the absolute number of Treg in the 
dLN (Figure 35, right panel). In order to confirm this result, we will also analyzed the 
expression of TGF- gene. 
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Figure 35. Analysis of EPO impact on Treg population. Left panel: gene expression of CD4 T cells from 
draining lymph node was analyzed on Light Cycler 480 (Roche) according to the manufacturer’s instructions. 
At d14 n=4, D16 n=1, D20 n=2. Right panel: Treg population was analyzed by FACS and their count was 
calculated by multiplying the percentage of FoxP3+ CD4+ CD3+ cells among alive cells by the number found 
when we count cells at the microscope. At day 14-20 n=5. Statistics: unpaired t test, *p<0.05, **p<0.01, 
***<0.001. 
 
 
 
Finally, the team is also interested to look at the impact of EPO on Th17 polarization. The 
analysis of RORt and IL-17 gene expression is ongoing. 
 
 
 
5.10 Analysis TIL cells in tumour 
In order to analyze the consequence of changes in Th polarization in dLN due to EPO 
treatment, we made the same analysis on Tumour-infiltrating lymphocytes. Unfortunately, 
no difference in the expression of genes specific for Th1, Th2 or Treg was found in the 
tumour (data not shown).  
However, the proportion of CD8 T cells was already found to be decreased after EPO 
treatment. By analyzing gene expression of these cytotoxic CD8 T cells, we found a decrease 
of Tbet et IFN- gene expression at D14 after tumour engraftment in EPO-treated mice 
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compared to controls (Figure 36). A slight expression of Tbet in CD8 correlates with an 
exhaustion phenotype of CD8, that may explain the decrease of IFN- gene expression. 
Further studies need to be done to confirm this preliminary result (n=1). Moreover, the 
analysis of Eomes and KLRG1 gene expression as well as protein presence in CD8 TIL, is 
needed to conclude on EPO impact on CD8 effector T cells. 
 
 
 
Figure 36. Analysis of EPO impact on CD8 TIL. Gene expression of CD8 T cells from tumour was analyzed 
on Light Cycler 480 (Roche) according to the manufacturer’s instructions. At d14 n=1. Statistics: unpaired t 
test, *p<0.05, **p<0.01, ***<0.001. 
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Innovative anticancer drugs with new molecular mechanisms of action are essential in 
chemotherapeutic treatment to kill specific cancer types, and to overcome toxic side effects 
as well as chemoresistance (Hutchinson et al., 2010). Current research efforts are focused on 
a deeper understanding of the cellular response and/or resistance to anticancer treatments, 
including the role of cell death pathways activation, such as apoptosis and autophagy, by 
using chemotherapeutics (Holohan et al., 2013). Recently, we have developed new 
biocompatible ruthenium-based nanosystems, proved to be particularly effective against 
specific cell lines derived from human solid tumours (Mangiapia et al., 2013; Simeone et al., 
2012; Riccardi et al., 2017). Starting from these encouraging data, we have first confirmed 
their efficacy focusing on a panel of human tumour cells arising from breast cancer. At the 
moment, the endocrine-responsive (ER) breast adenocarcinoma MCF-7 and the triple-
negative breast adenocarcinoma (TNBC) MDA-MB-231 cell models account for the great 
majority of investigations on breast cancer cells and are considered the most reliable in vitro 
models of breast cancer together with their variants CG5, and MDA-MB-436 and MDA-
MB-468, respectively (Lacroix et al., 2004; Holliday et al., 2011). All these cells are 
sensitive to cisplatin in vitro, so that cisplatin is currently the drug-based option in the 
therapeutic armamentarium. Although new types of ruthenium complexes with bigger 
anticancer activity in vitro have been meanwhile reported (Koceva-Chyła et al., 2016), the 
induction of comparable or even greater cytotoxic effects than cisplatin have been herein 
confirmed for nucleolipidic Ru(III) formulations. Then, aiming at an in-depth investigation 
of their mode of action, we have shown that amphiphilic ruthenium complexes, properly 
delivered by suitable nano-systems, are able to kill cancer cells by activating specific 
apoptotic processes, coupled in some cases to cellular autophagy. Indeed, in the last decade 
many different ruthenium compounds have been tested for their anticancer properties. 
However, all the reported studies have not clearly evidenced a unique mode of action at 
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cellular level, nor unambiguously defined a specific mechanism of action at molecular level 
(Alessio et al., 2016; Riccardi et al., 2017). In-depth bioanalytical studies have been so far 
performed especially for cisplatin, which have validated nuclear DNA as the main final drug 
target causing adducts formation and DNA damage, leading to cell division inhibition and 
cytotoxicity. In analogy with cisplatin, some of us have recently demonstrated that also 
AziRu and NAMI-A can interact with DNA model systems, with Ru(III) ions being 
incorporated into oligonucleotide structures via stable linkages (Musumeci et al., 2015). 
However, since an increasing number of evidences demonstrate that both ruthenium(II) and 
(III)-based drugs are able to interact with both intra- and extra-cellular protein targets, 
currently other molecular mechanisms of action cannot be excluded. Beyond molecular 
targeting, we have observed an invariable activation of programmed cell death pathways 
which confirms that the primary mode of action in breast cancer models of AziRu via 
DoHuRu/POPC and DoHuRu/DOTAP formulations is the induction of apoptosis. These 
data are largely in accordance with several reports highlighting the occurrence of distinct 
hallmarks of apoptosis after ruthenium administration in vitro. Cellular morphological 
changes and DNA fragmentation provided additional evidence of an apoptosis-inducing 
activity at the basis of the anticancer properties of AziRu. The regulation of apoptotic cell 
death orchestrated by intracellular caspases plays a fundamental role in the response to 
chemotherapeutics, as evasion of apoptosis is one of the central features of malignant 
progression as well as of drug resistance. Indeed, survival of malignant mammary cells is a 
key event in disease occurrence and progression, but also in therapy failure and 
chemoresistance development. Physiological mammary cells growth is controlled by a 
balance between cell proliferation and apoptosis. A large body of evidence has clarified that 
tumour growth is not just a result of uncontrolled proliferation but also of reduced apoptosis, 
so that the balance between proliferation and apoptosis is crucial in determining the overall 
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growth or regression of the tumour in response to chemotherapy. Two main pathways of 
caspase activation have been described in mammalian cells, which result in final control of 
apoptosis. In the intrinsic pathway, typically activated by intracellular stress signals, pro-
apoptotic cell death factors belonging to the Bcl-2 family increase mitochondrial 
permeability and release of cytochrome c, as well as of other proteins from the 
intermembrane space of mitochondria. Apaf-1, a downstream mediator of apoptosis, along 
with cytochrome c, associates with caspase-9 in cytoplasm and leads to its activation. The 
resulting apoptosome initiates a cascade of effector caspases, which include caspases-3, -6, 
and -7. In turn, the active caspase-3 triggers DNA fragmentation factor (Caspase-Activated 
DNase, CAD) and promotes DNA internucleosomal cleavage. All the formulations 
containing nucleolipidic Ru(III)-complexes we have tested activate the mitochondrial 
apoptotic cell death pathway in breast cancer cells, as highlighted by a remarkable activation 
of caspase-9. Interestingly, this occurs independently of the cell ability to complete apoptosis 
process via the executioner caspase-3, as demonstrated by Ru-dependent activation of 
apoptosis in MCF-7. This adenocarcinoma model is known to be resistant to some 
chemotherapeutics due to a deletion in the CASP-3 gene that leads to an inherited deficiency 
of caspase-3. Caspase-3 - commonly turned on by numerous death signals - cleaves a variety 
of important cellular proteins and is ultimately responsible for apoptotic DNA 
fragmentation. Despite the lack of caspase-3 expression, liposomes containing nucleolipidic 
Ru(III)-complexes have hitherto shown to be particularly effective on this in vitro model. It 
has been also reported that MCF-7 undergoes cell death by apoptotic stimuli in the absence 
of the typical DNA fragmentation, and recent observations further suggest that large and 
small DNA fragments coupled to even single-strand cleavage events occur during apoptotic 
death. Consistently with our results, these observations have raised relevant questions on the 
degradation pattern of nuclear DNA in agarose gel electrophoresis detection, which remains 
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controversial. However, morphological changes and MCF-7 cell death were independent of 
caspase-3 and may correlate with the activation of different apoptotic pathways and other 
effector caspases, such as caspase-6 or -7. As far as the activation of programmed cell death 
pathways is concerned, DoHuRu/DOTAP formulation seems capable to concurrently 
activate the two major pathways of apoptosis in a cell-specific mode. In fact, MDA-MB-231 
cells, undergoing the apoptotic mitochondrial pathway after exposure to DoHuRu/DOTAP, 
show an apparent proteolytic processing of pro-caspase-8 to form various fragments, 
including the active p18 and p10. The extrinsic pathway is activated by extracellular ligands 
able to bind to death receptors on the cell surface, which leads to the formation of the death-
inducing signaling complex (DISC). This death receptor pathway is triggered by members 
of the death receptor superfamily such as CD95 and tumour necrosis factor receptor. 
Formation of a death-inducing signaling complex induces caspase-8 activation and thereby 
the downstream caspase cascade (Kiraz et al., 2016). We hypothesize that the cationic 
DOTAP nanoaggregate, by means of its inherent surface charge, can interact in peculiar 
manner with the external surface of cell membranes, as suggested by the faster cellular 
uptake kinetics compared to POPC formulations observed in a previous study. Although a 
hypothesis, exclusive molecular interactions coupled to local drug release could stimulate 
specific surface receptors involved in the activation of the extrinsic pathway. Indeed, not 
infrequently the killing of tumour cells by anticancer chemotherapeutics has been linked to 
activation of extrinsic apoptosis pathways. These outcomes are consistent with former 
investigations and demonstrate that some ruthenium(II) and (III) complexes can 
simultaneously trigger intrinsic and extrinsic apoptosis pathways. As far as the Bcl-2 family 
proteins are concerned, we believe that some central aspects closely linked to ruthenotherapy 
have emerged. Members of this family are regulatory proteins involved in the control of cell 
death, by either inducing (pro-apoptotic factors) or inhibiting (anti-apoptotic factors) 
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apoptosis. Bcl-2 is a crucial anti-apoptotic protein to be regarded as an oncogene, playing an 
important role in promoting cellular survival by inhibition of pro-apoptotic proteins. On the 
other hand, the pro-apoptotic effectors of the Bcl-2 family, including Bax, normally act on 
the mitochondrial membrane to promote permeabilization coupled to the release of both 
cytochrome c and ROS as important signals in the apoptosis cascade. Several clinical studies 
have provided support for an overexpression of the antiapoptotic Bcl-2 protein as a negative 
prognostic marker in various tumours. Alternatively, decreased Bax levels have been found 
in correlation with shorter survival in patients with breast cancer and colorectal cancer 
(Sturm et al., 2000). In MCF-7 and MDA-MB-231 we found an important effect induced by 
both DoHuRu/POPC and DoHuRu/DOTAP treatment on the cellular content of Bcl-2 and 
Bax, which could be correlated to the induction of the mitochondrial cell death pathway. The 
significant increase in Bax/Bcl-2 ratio detected in treated cells with respect to untreated cells 
could have an important impact in the regulation of cell fate by interfering with breast cancer 
cell survival. Indeed, in accordance with experimental and clinical investigations, tumours 
dependent on Bcl-2 family members are likely sensitive to Bcl-2 modulation in order to 
survive; in turn high Bax expression has been associated with a better response to 
chemotherapy in many cancers forms. Consistently with our results, it should be possible to 
circumvent the inherent apoptosis deficiency of malignant cells by directly affecting the 
mitochondrial function. In this way, following mechanisms yet to be clarified, the ruthenium 
complexes may interact with mitochondrial targets, possibly via selective accumulation and 
ROS generation. At the same time, dysfunction of mitochondria might be responsible for 
autophagic cell death. More and more studies underline the important interplay between 
apoptosis and autophagy, and suggest that apoptosis activation is often related to increased 
autophagy processes. As in the case of apoptosis, autophagy plays a vital role in cellular 
proliferation and survival, and dysregulated autophagy activation has been described in 
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many pathologies, including cancer. Although the role of the autophagic programmed cell 
death in neoplastic development remains to be clarified in vivo, cancer cells with up-
regulated autophagy exhibit a less aggressive behavior as well as an increased susceptibility 
to chemotherapy. Autophagic degradation of cellular contents is employed by eukaryotes 
from yeast to man in order to maintain cellular homeostasis and protect against disease. The 
process involves the coordinated activity of a family of autophagy-related (ATG) proteins 
to mediate sequestration of cargo in a double-membrane vesicle (autophagosome) that then 
fuses to a lysosome (autolysosome) filled with, among other components, lysosomal 
enzymes. Studies now suggest that multiple forms of selective autophagy are continuously 
active at some basal level in order to maintain cellular homeostasis, whereas specific stimuli 
can activate selective autophagic pathways in order to address particular stressor. Coincident 
with its importance in maintaining cellular homeostasis, the disruption of selective 
autophagy pathways has been shown to play a role in diverse disease processes including 
cancer. In particular, studying the role of selective autophagy pathways has in part unraveled 
the complex role of autophagy in cancer as tumour suppressive and pro-tumourigenic 
dependent on context. Importantly, understanding the precise roles of various forms of 
selective autophagy in maintaining tumour growth provides the opportunity to target these 
processes more selectively. In this frame, the molecular mechanisms of selective autophagy 
receptor action and regulation are complex. The autophagy core machinery consists of a set 
of ATG proteins. Among these, LC3 is at the core of the autophagic process. As 
demonstrated by an ever-growing number of evidence, it is the only essential autophagy 
protein that can be found in the autophagosome after its completion, and therefore is the 
marker par excellence to experimentally monitor the fate of these vesicles. As above 
mentioned, the role of autophagy in cancer is extremely complex, as demonstrated by a 
growing literature describing situations where autophagy can either promote or inhibit 
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tumourigenesis. The most likely explanation is that the role of autophagy in cancer is 
dynamic with both tumour-suppressive and pro-tumourigenic roles, which depend on 
multiple factors including tumour stage, cellular context, and tissue of origin. Autophagy 
was initially considered a mechanism by which to suppress tumour initiation. However, 
recent work has brought to light tumour-suppressive selective autophagy pathways that can 
mitigate oncogenic signals and conversely selective autophagic pathways that support 
tumour maintenance and progression. More direct evidence of autophagy as a tumour 
suppressor came from mouse genetic studies of core autophagy machinery including ATG5, 
ATG7, and BECN1 (Beclin 1) showing that when autophagy is impaired, there is an increase 
in tumour initiation. Indeed, from a mechanistic standpoint, inhibition of autophagy leads to 
an accumulation of reactive oxygen species, increased DNA damage, and mitochondrial 
defects, all implicated in tumourigenesis. Another potential mechanism for tumour 
suppression by autophagy is via its role in cellular senescence. Cellular senescence is a 
program of permanent arrest of the cell division cycle that can be induced by cells in response 
to oncogenes in order to prevent malignant transformation. For sure, while the situation is 
very complex in vivo, the activation in vitro of autophagic pathways represents another 
challenging possible molecular mechanism to inhibit uncontrolled proliferation of cancer 
cells. However, studying the role of autophagy pathways in cancer has in part unraveled the 
complex role of autophagy in cancer as tumour suppressive and pro-tumourigenic, 
dependent on context. Importantly, understanding the precise roles of various forms of 
selective autophagy in maintaining tumour growth provides the opportunity to target these 
processes more selectively. 
Since the effectiveness of many apoptosis-inducing chemotherapies can be affected by 
specific mutations in genes orchestrating apoptotic regulation, the activation of alternative 
cell death pathways, in tandem with or in the absence of an efficient apoptotic machinery, 
111 
 
may represent an attractive goal for novel metal-based chemotherapeutics. In this 
perspective, recent evidence supports the occurrence of the simultaneous induction of 
apoptosis and autophagy in cancer cells as a result of specific signaling. In addition, 
autophagy can be also activated upon exposure to genotoxic compounds, including several 
metal-based drugs able to target DNA. The induction of autophagy in the case of cationic 
nucleolipidic formulations could be linked to the ruthenium-induced down-regulation of the 
prosurvival protein Bcl-2, evident in both MCF-7 and MDA-MD-231 cells. Indeed, 
disturbances in the interaction between Beclin 1 and Bcl-2 family proteins, by which Beclin 
1 is inhibited in normal conditions, has been established to stimulate cellular autophagy. 
Thus Ru(III) complexes activity in inhibiting breast cancer cells proliferation via 
DoHuRu/DOTAP administration would lie in the crosstalk connecting the main molecular 
mechanisms involved in the regulation of apoptosis and autophagy processes. Nevertheless, 
the existence of other non-apoptotic nor necrotic cell death pathways, triggered upon 
exposure to ruthenium-containing nanoaggregates we have documented in breast cancer 
models, needs further and more targeted studies. According to our previous findings 
(Mangiapia et al., 2012) and to recent literature reports (Koceva-Chyła et al., 2016; Qian et 
al., 2013) it cannot be excluded that the simultaneous activation of different mechanisms of 
cell death can be caused by multiple potential interactions at the subcellular/molecular level, 
both nuclear and cytosolic. Nevertheless, the activation of multiple death pathways by metal-
based chemotherapeutics in aggressive cancer diseases with limited treatment options is a 
largely desired goal, in order to possibly restrict the onset of chemoresistance as well as to 
efficiently counteract uncontrolled proliferation (Figure 37). 
Furthermore, giving the great importance of the tumour microenvironment on cancer growth 
as well as on the efficacy of the chemotherapy, upcoming investigations on the evaluation 
of the Ru(III)-containing liposomes impact on the tumour-infiltrating immune system cells 
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are underway to strengthen knowledge in favor of future in vivo applications for these high 
potential candidate drugs. 
For a long time, tumour-related investigations were focused only on cancer cells, ignoring 
the environment created around the tumour. Indeed, it has been known that tumours are 
heterogeneous organs, rich in various number of components which are very important for 
the cancer growth and proliferation. In this setting, given that the immune cell compartment 
within the tumour is recognized as major driver, directly or indirectly, of angiogenesis and 
vascular remodeling in addition to the tumour cell itself (Li and Zhang, 2017), one of the 
interests of cell laboratories is to investigate the role of tumour-infiltrating immune system 
cells (such as TAM, TIL, CD4 T cells) and their secreted components, as well as their 
possible modulation. 
In particular, CD4 T cells play essential roles in the function of the immune system. They 
are able to regulate different functions, such as to regulate/suppress immune responses both 
controlling autoimmunity and adjusting the extent and persistence of responses. They are 
divided into two major groups, designated Th1 and Th2 cells by Mosmann and Coffman, 
which are distinguished by the cytokines produced and through the expression of different 
patterns of cell surface molecules. Other types of CD4 T cells recognized are T regulators 
(Treg) - important in the tolerance and so able to the inhibition of immune cells - NKT, but 
also into Th9 or Th17 ( Zhu et al., 2010). 
Moreover, recent studies have shown a possible role of EPO in regulating tumour-infiltrating 
immune system cells within its micro environment, since EPO receptors -endowed with 
critical functions - have been identified on these cells surface (Feldman et al., 2006; Um et 
al., 2006; Henke et al., 2006). 
Erythropoietin (EPO), the most widely used erythropoiesis-stimulating agent (ESA), is 
largely used in the treatment of anemia associated with chronic kidney disease (CKD) 
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(Eschbach et al., 1987), and also in cancer-related anemia in association with conventional 
chemotherapy (Littlewood et al., 2002). 
Although erythropoiesis-stimulating agents (ESAs) reduce anemia in patients with cancer 
and could improve their quality of life, these drugs have been reported to might increase 
mortality (Bohlius et al., 2009). Indeed, they could induce tumour progression independently 
of the type of cancer or the anti-cancer treatment (Henke et al., 2003; Bohlius et al., 2009)., 
even if mechanisms underlying the role of EPO/ESA on tumour proliferation still remain 
unknown and highly controversial. 
Interestingly immunosuppressive role of EPO in humans has already been described by 
decreasing T cell function (Cravedi et al., 2003). In another hand, in an auto-immune 
encephalomyelitis mouse model, the beneficial effect of EPO was attributed to a Th2-
polarized immune response. Moreover, EPO was shown in a mouse model of infection, to 
inhibit macrophage activation, through NF-κB pathway inhibition, impairing antibacterial 
function (Nairz et al., 2011). 
In particular, studies carried out by Hacein-Bey-Abina’s team show that EPO decreases the 
differentiation of CD4 T cells into Th1 profile, which is an anti-tumourigenic profile. 
Moreover, whereas it is well known that Th1/Th17 cytokines inhibit Th2 development (and 
vice and versa), we have observed that the gene expression level of IL-4 – principal cytokine 
secreted by Th2 - is also reduced in EPO treated mice. 
Moreover, preliminary studies on the PNM:MDSC genes expression profile would indicate 
an increase in the expression of cytokines with immunosuppressive action but these results 
cannot be confirmed and so for the time we cannot conclude on the commitment toward the 
N2 profil, but further experiments are ongoing. 
Therefore, in agreement with literature data, these results lastly demonstrate that in vivo EPO 
administration leads to an increase in tumour growth and proliferaition, probably due to a 
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direct effect on the immune system cells polarization within tumour microenvironment, 
showing an immunosuppressive profile along with a pro-tumourigenic activity. 
 
 
 
Figure 37. Mechanism of action of ruthenium-based nucleolipidic nanosystems, assumed on the basis of a 
series of experimental evidences. From the selective cellular uptake in the tumor microenvironment to the 
possible interaction with specific mitochondrial and nuclear biomolecular targets, responsible for the activation 
of specific programmed cell death pathways. 
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